US20180305416A1 - Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof - Google Patents
Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof Download PDFInfo
- Publication number
- US20180305416A1 US20180305416A1 US15/827,151 US201715827151A US2018305416A1 US 20180305416 A1 US20180305416 A1 US 20180305416A1 US 201715827151 A US201715827151 A US 201715827151A US 2018305416 A1 US2018305416 A1 US 2018305416A1
- Authority
- US
- United States
- Prior art keywords
- hbha
- protein
- fusion protein
- subject
- heparin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 title claims abstract description 149
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 50
- 241000186359 Mycobacterium Species 0.000 title claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 68
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 49
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 claims abstract description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 23
- 230000000890 antigenic effect Effects 0.000 claims abstract description 20
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 230000028993 immune response Effects 0.000 claims description 27
- 150000001413 amino acids Chemical group 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 230000004927 fusion Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 11
- 230000009257 reactivity Effects 0.000 claims description 10
- 206010065048 Latent tuberculosis Diseases 0.000 claims description 9
- 208000033353 latent tuberculosis infection Diseases 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 230000005847 immunogenicity Effects 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 18
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract description 8
- 238000013518 transcription Methods 0.000 abstract description 4
- 230000035897 transcription Effects 0.000 abstract description 4
- 230000004992 fission Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 201000008827 tuberculosis Diseases 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 238000004949 mass spectrometry Methods 0.000 description 12
- 230000003115 biocidal effect Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000011713 pantothenic acid Substances 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229930027917 kanamycin Natural products 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 229940014662 pantothenate Drugs 0.000 description 8
- 235000019161 pantothenic acid Nutrition 0.000 description 8
- 101150003612 pfo gene Proteins 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000011987 methylation Effects 0.000 description 7
- 238000007069 methylation reaction Methods 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 241000193468 Clostridium perfringens Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000186366 Mycobacterium bovis Species 0.000 description 5
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000007420 reactivation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000003118 sandwich ELISA Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000012808 vapor phase Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000032420 Latent Infection Diseases 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 102000016397 Methyltransferase Human genes 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 241000187480 Mycobacterium smegmatis Species 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012297 crystallization seed Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000007773 growth pattern Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 229940094937 thioredoxin Drugs 0.000 description 3
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 3
- 229960004224 tyloxapol Drugs 0.000 description 3
- 229920001664 tyloxapol Polymers 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 108010065693 Clostridium perfringens theta-toxin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000036981 active tuberculosis Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010062636 apomyoglobin Proteins 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102000021178 chitin binding proteins Human genes 0.000 description 2
- 108091011157 chitin binding proteins Proteins 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010013453 Disseminated tuberculosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 108700027766 Listeria monocytogenes hlyA Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101100129629 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) mrtA gene Proteins 0.000 description 1
- 101100292591 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) mtrA1 gene Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000949972 Mycobacterium bovis BCG str. Pasteur 1173P2 Species 0.000 description 1
- 108700008972 Mycobacterium tuberculosis HbhA Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000000021 endosomolytic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- -1 flavorings Substances 0.000 description 1
- 101150075316 folE gene Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 101150007644 hspX gene Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 238000013411 master cell bank Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 101150069500 mtrA gene Proteins 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 108010075210 streptolysin O Proteins 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
Definitions
- the invention generally relates to recombinant Mycobacteria which contain and express sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein.
- the fusion protein contains an amino terminal mycobacterial antigen Ag85B leader sequence, and transcription of the fusion protein is driven by a suitable promoter, e.g. the Ag85B promoter.
- the invention also provides methods of making and using the recombinant Mycobacteria and the recombinant fusion protein, e.g. as vaccinogens.
- Tuberculosis is a global public health problem resulting in 8 million new cases and 2 million deaths each year.
- a particularly problematic aspect of TB diagnosis and treatment is the ability of the Mycobacterium tuberculosis (Mtb) bacillus to enter a latent, asymptomatic state and to persist in latently infected individuals for long periods of time.
- Mtb Mycobacterium tuberculosis
- Such individuals are susceptible to reactivation of the disease due to, for example, immune suppression caused by diseases or conditions such as HIV, treatments such as chemotherapy and the use of corticosteroids, the waning of immunity that accompanies aging, etc.
- BCG Mycobacterium bovis
- HBHA heparin-binding hemagglutinin
- Mtb heparin-binding hemagglutinin
- the HBHA may be produced by one of two methods: either by 1) producing recombinant non-methylated HBHA protein in a heterologous cell ( Escherichia coli or Mycobacterium smegmatis ) and then post-translationally methylating the purified recombinant HBHA using a chemical or enzymatic method; or 2) using a recombinant cell to co-express nucleotide sequences encoding HBHA and a mycobacterial methyltransferase.
- a heterologous cell Escherichia coli or Mycobacterium smegmatis
- Method 1 involves multiple steps for protein preparation; method 2 involves the use of a heterologous cell that is not administrable as a vaccine. Further, the bacterial strains employed by Pethe were antibiotic resistant, and no discussion of optimizing protein yields is provided. Thus, there remains a need in the art for a recombinant Mtb that is capable of being used as a vaccinogen, and/or for producing sufficient quantities of HBHA to be clinically relevant, both in vitro and in vivo, and/or for producing large quantities of HBHA in a manufacturing setting for later use in clinical applications.
- the invention provides recombinant Mycobacteria (rMyc) which contain and express nucleic acid sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein.
- the fusion protein includes a mycobacterial antigen Ag85B leader peptide attached at the amino terminus.
- the fusion protein is post-translationally methylated, resulting in a protein with a methylation pattern that is the same as or highly similar to that of native HBHA.
- the resulting fusion protein is thus highly antigenic, and copious amounts of the highly antigenic fusion protein can be produced using the methods of the invention. Transcription of the fusion protein is driven by a suitable promoter, which can be constitutive or inducible.
- the promoter is the Ag85B promoter sequence
- the invention also provides methods of making the rMyc (e.g. on an industrial scale), methods of using the rMyc e.g. as a vaccinogen and/or to elicit an immune response, or to make the fusion protein; or to produce seed cultures; and methods of making and using the fusion protein e.g. as a vaccinogen and/or to elicit an immune response, or as a diagnostic, for example, to detect latent tuberculosis infections.
- Mycobacterium that is genetically engineered to contain and express a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, the fusion sequence being operably linked to a promoter.
- the Mycobacterium is, for example, Mycobacterium tuberculaosis, Mycobacterium bovis , or Mycobacterium smegmatis .
- the Mycobacterium is Mycobacterium bovis e.g. Mycobacterium bovis (Bacille Calmette-Guérin) (BCG).
- the BCG is a BCG Danish Statens Serum Institut (SSI) strain and may, for example, express a pfo gene such as a pfo gene from Clostridium perfringens .
- the Mycobacterium is an auxotroph, for example, a pantothenic acid auxotroph.
- the nucleic acid fusion sequence is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the polypeptide encoded by the nucleic acid fusion sequence has an amino acid sequence: mrrlcaridi wpphtvcsgp strrhtgqrg tsmatdvsrk irawgrrlmi gtaaavvlpg lvglaggaat agafsmaens niddikapll aalgaadlal atvnelitnl reraeetrtd trsrveesra rltklqedlp eqltelrekf taeelrkaae gyleaatsry nelvergeaa lerlrsqqsf eevsaraegy vdqaveltqe algtvasqtr avgeraaklv gielpkkaap akkaapakka apakkaaakk apakkaakk vtqe algt
- the mycobacterial HBHA protein is Mycobacterium tuberculosis HBHA.
- the promoter is a mycobacterial Ag85B promoter
- the invention also provides an isolated recombinant nucleic acid molecule with a nucleotide sequence:
- the invention also provides a recombinant fusion protein which comprises an Ag85B leader sequence covalently attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein.
- HBHA mycobacterial heparin-binding hemagglutinin
- the entire fusion protein is transcribed as one mRNA and translated as a single polypeptide (protein).
- the recombinant fusion protein has an amino acid sequence: mrrlcaridi wpphtvcsgp strrhtgqrg tsmatdvsrk irawgrrlmi gtaaavvlpg lvglaggaat agafsmaens niddikapll aalgaadlal atvnelitnl reracetrtd trsrveesra rltklqedlp eqltelrekf taeclrkaae gyleaatsry nelvergeaa lerlrsqqsf ccvsaraegy vdqavcltqec algtvasqtr avgeraaklv gielpkkaap akkaapakka apakkaaakk apakkaakk vtqk (SEQ ID
- the invention also provides methods of producing a recombinant fusion protein that comprises an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein.
- the method comprises: 1) transfecting a bacterial cell such as a Mycobacterium cell with a nucleic acid sequence encoding the recombinant fusion protein; 2) growing the transfected bacterium (e.g. a Mycobacterium ) cell under conditions which allow the bacterium cell to produce the recombinant fusion protein; and 3) obtaining the recombinant fusion protein.
- the transfecting is carried out by electroporation.
- the invention also provides methods of determining whether a subject has a latent tuberculosis infection.
- the method comprises determining the presence or absence of immune reactivity of the patient to a recombinant fusion protein comprising an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein.
- the presence of immune reactivity indicates that the subject has a latent tuberculosis infection. Determining the presence or absence of immune reactivity may include, for example, 1) obtaining a biological sample from the subject, and 2) detecting the presence or absence of immune reactivity in the biological sample.
- Exemplary biological samples include but are not limited to sputum samples and serum samples.
- determining the presence or absence of immune reactivity may include the step of detecting includes 1) intradermally injecting the recombinant fusion protein into the subject, and 2) determining the presence or absence of immune reactivity at the site of intradermal injection.
- the invention also provides methods of eliciting an immune response against Mycobacterium tuberculosis in a subject in need thereof.
- This method comprises the step of administering to the subject an amount of a recombinant fusion protein comprising an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein sufficient to elicit an immune response in said subject, and may be referred to as a “therapeutic” amount.
- the immune response that is elicited is production of one or more of B cells, antibodies and T cells.
- the immune response is a protective immune response.
- the invention also provides methods of eliciting an immune response against Mycobacterium tuberculosis in a subject in need thereof.
- the method comprises administering to the subject a recombinant Mycobacterium comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein.
- the fusion sequence is operably linked to a promoter, and the recombinant Mycobacterium is administered in an amount sufficient to elicit an immune response in the subject.
- the immune response is production of antibodies.
- the immune response is a protective immune response.
- the invention also provides methods of producing recombinant heparin-binding hemagglutinin (rHBHA) protein.
- the methods comprise 1) growing a culture of recombinant Mycobacteria comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, wherein said fusion sequence is operably linked to a promoter, under conditions in which the rHBHA is produced.
- the method further comprises obtaining the rHBHA protein from the culture.
- the method may also include purifying the rHBHA protein, e.g. after the step of obtaining the rHBHA.
- Purifying may be carried out using one or more physico-chemical technologies such as, for example, chromatography (e.g. one or more of affinity, size exclusion, ion exchange, or hydrophobic interaction chromatography); and/or cell disruption techniques (e.g. one or more of high pressure cell disruption, bead beaters, homogenization, sonication, centrifugation, and the like).
- the method may also include verifying the identity of the rHBHA protein.
- the step of growing is carried out in culture by shaking or by fermentation. In some embodiments, growing is carried out using a hatch or a continuous culture.
- a seed lot comprises 1) recombinant Mycobacteria comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, wherein the fusion sequence is operably linked to a promoter; and 2) medium suitable for maintaining the recombinant Mycobacteria in a viable state during storage of the seed lot.
- HBHA mycobacterial heparin-binding hemagglutinin
- the invention also provides methods of preparing a composition comprising a heparin-binding hemagglutinin (HBHA) protein.
- the method comprises 1) growing a culture of recombinant Mycobacteria comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, wherein the fusion sequence is operably linked to a promoter; 2) obtaining the rHBHA protein from the culture; 3) purifying the rHBHA protein; and 4) combining purified rHBHA protein with a physiologically acceptable carrier.
- the growing may be carried out in shake culture or by fermentation.
- method may further comprise adding one or more additional therapeutically useful agents, including but not limited to, one or more antigens that are not HBHA, one or more adjuvants, and one or more immunogenicity enhancers, to the rHBHA and physiologically acceptable carrier.
- additional therapeutically useful agents including but not limited to, one or more antigens that are not HBHA, one or more adjuvants, and one or more immunogenicity enhancers, to the rHBHA and physiologically acceptable carrier.
- additional therapeutically useful agents including but not limited to, one or more antigens that are not HBHA, one or more adjuvants, and one or more immunogenicity enhancers, to the rHBHA and physiologically acceptable carrier.
- FIG. 1A shows the DNA sequence (SEQ ID NO:1) encoding the HBHA fusion protein.
- the Ag85B leader peptide is encoded by the underlined nucleotides.
- FIG. 1B shows the DNA sequence encoding the HBHA fusion protein as in FIG. 1A but also shows the exemplary Ag85B promoter sequence in bold (SEQ ID NO: 2).
- FIG. 2 shows the in silico cloning and complementation strategy.
- FIG. 3A shows the schematic of the pantothenate complementation plasmid (pKAMCB2) and FIG. 3B shows the cloning of HBHA gene into pKAMCB2.
- FIG. 4 shows the schematic unmarking of the pKAMCB2+HBHA clone for kanamycin resistance.
- FIG. 5A shows the amino acid sequence of recombinant HBHA (SEQ ID NO: 3) compared with FIG. 5B , which shows the native HBHA from which amino terminal methionine has been cleaved (SEQ ID NO: 4) and FIG. 5C , which shows the schematic position of the Ag85B leader at the N-terminus.
- FIG. 6A shows the recombinant BCG colonies PCR screened for the HBHA gene.
- FIG. 6B shows the presence of plasmid backbone and
- FIG. 6C shows the absence of the kanamycin resistance marker. Clone no. 5 tested positive for the presence of HBHA gene, intact plasmid backbone and the absence of kanamycin gene.
- FIG. 7 shows the growth kinetics of AERAS 445, a pantothenate auxotroph of a BCG Danish SSI strain expression a Clostridium perfringens pfo gene, and further modified to encode the HBHA fusion protein of the invention.
- FIG. 8 shows the Western blot over expression of HBHA in AERAS-445 using 4057D2 anti-HBHA monoclonal antibody. Arrows 1 and 2 indicate endogenous HBHA and recombinant HBHA proteins.
- FIG. 9 shows the Western blot over expression of HBHA in AERAS-445 using 1G10 antibody. Lanes: 1 AERAS-401; 2 AERAS-413; 3 AERAS 445. Arrows 1 and 2 indicate native HBHA and recombinant HBHA proteins.
- FIG. 10 shows the Western blot HBHA expression using 1G10 antibody in different stages of manufacturing AERAS-445.
- Arrows 1 and 2 indicate native HBHA and recombinant HBHA proteins.
- Arrows 1 and 2 indicate endogenous HBHA and recombinant HBHA proteins.
- FIGS. 11A and 11B show the yields of HBHA protein in strains determined by sandwich ELISA; FIG. 11A , depicted graphically, and FIG. 11B , depicted as a bar graph.
- FIG. 12 shows the mass spectrometry analysis of rHBHA purified from AERAS 445.
- FIG. 13 shows the mass-spectrometry analysis of the C-terminal end of rHBHA purified from AERAS 445.
- FIGS. 14A and 14B show the antigenicity analysis by ELISA using monoclonal antibodies 3921E4 ( FIG. 14A ): and 4057D2 ( FIG. 14B ).
- the invention provides recombinant Mycobacteria (rMyc) which contain and express nucleic acid sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein.
- the recombinant Mycobacteria can be administered in vaccine preparations since they are not antibiotic resistant and are attenuated.
- the fusion protein includes, attached to its amino terminus, a mycobacterial antigen Ag85B leader peptide sequence.
- the rMycs of the invention produce large amounts of the fusion protein, with transcription being driven by a suitable promoter.
- the fusion protein may also be recovered from the rMyc in an industrial manufacturing process and be used as part of a vaccine preparation or diagnostic.
- the nucleic acid sequence that encodes the antigenic recombinant fusion protein of the invention is the DNA sequence depicted in FIG. 1A (SEQ ID NO: 1) As can be seen, the nucleic acid encodes the Ag85B leader sequence at nucleotides 1 to 225 (underlined) and the HBHA protein at nucleotides 226 to 825. In addition, in the exemplary embodiment depicted in FIG. 1B , at its 5′ end, the nucleic acid contains the Ag85B promoter sequence at nucleotides 1 to 184 (shown in bold). In the embodiment illustrated in FIG. 1B , the translated fusion protein per se that is produced by the cell is thus encoded by nucleotides 185 to 1009, i.e. the promoter region is not translated.
- the invention encompasses a nucleic acid with a sequence which is or which includes the sequence as set forth in SEQ ID NO: 1 (see FIG. 1A ). In another embodiment, the invention encompasses a nucleic acid with a sequence that is or includes the sequence as set forth in SEQ ID NO: 2 (sec FIG. 1B ). In another embodiment, the invention encompasses a nucleic acid with a sequence that is or includes the sequence as set forth in SEQ ID NO: 3 (see below).
- the invention also encompasses DNA that is complementary to SEQ ID NOS: 1 and 2, and also mRNA that is translated from SEQ ID NOS: 1 and 2 (or complements thereof), or cDNA based on such mRNA (as well as various DNA-RNA hybrids of these), and encompasses both single and double stranded nucleic acids.
- SEQ ID NOS: 1 and 2 DNA that is complementary to SEQ ID NOS: 1 and 2
- cDNA based on such mRNA as well as various DNA-RNA hybrids of these
- sequences with at least about 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, or about 99% homology to SEQ ID NOS: 1 and 2 may also be employed, so long as the translated polypeptide is able to be methylated and is sufficiently antigenic to elicit an immune response in a subject to whom it is administered.
- levels of homology are also applicable to the corresponding complementary DNA, RNA, etc. described above.
- Those of skill in the art are familiar with automated programs or software for determining homology levels.
- the nucleic acid sequence that encodes the fusion protein may also include various helpful sequences, e.g. restriction sites for ease of genetic manipulation of the sequence.
- the % homologies described herein can be determined, for example, using the Smith-Waterman homology search algorithm as implemented in MSPRCH program (Oxford Molecular) using anaffine gap search with the following search parameters: gap open penalty of 12, and gap extension penalty of 1.
- Exemplary variations of the recombinant sequence include but are not limited to: the substitution of codons which encode conservative amino acid replacements of some encoded residues; the insertion of e.g. sequences encoding linker or spacer sequences, e.g. between the promoter and the leader sequence, or between the leader sequence and the HBHA encoding sequence; various changes to the sequence to facilitate handling or manipulation of the sequence, e.g. the insertion of or change in restriction enzyme sites which flank the sequence; portions of a vector (e.g. 5′ or 3′ overhangs or sequences complementary to the same), sequences which encode various tags as described below, etc.
- a promoter sequence that is operably linked to SEQ ID NO: 1.
- operably linked it is meant that the promoter sequence and SEQ ID NO: 1 are arranged within a nucleic acid molecule such that expression of SEQ ID NO: 1 is driven or controlled by the promoter.
- the promoter may directly precede SEQ ID NO: 1 in the molecule.
- some additional sequences may intervene.
- other control elements that aid in expression of SEQ ID NO: 1 may also be included in the nucleic acid molecule, e.g. various enhancer sequences, etc.
- promoters that may be used in the practice of the invention include but are not limited to, for example, promoters of genes hsp60, hspX, pBlaF or mtrA, etc.
- the promoter is the Ag85B promoter, and is arranged with respect to SEQ ID NO: 1 as is depicted in FIG. 1B (the sequence in bold), i.e. is placed directly upstream of SEQ ID NO: 1.
- the fusion protein of the invention is an antigenic recombinant fusion or chimeric protein (polypeptide) which comprises: 1) a mycobacterial HBHA protein sequence, or a functional portion thereof; and 2) an Ag85B leader peptide (or functional portion thereof) attached to or associated with the amino terminus of the HBHA protein.
- a mycobacterial HBHA protein sequence or functional portion thereof we mean an HBHA protein with a sequence as depicted in FIG. 5B (SEQ ID NO: 4) or peptide or polypeptide fragments thereof which are antigenic, i.e. which elicit the production of antibodies which bind to native HBHA, when administered as a component of the fusion protein of the invention.
- Such fragments may also be sufficient to interact with and bind to heparin.
- antigenic peptide fragments of about 50 amino acids or less in length which are comprised within about the last 30 to 50 amino acids located at the carboxyl terminus of SEQ ID NO: 4 may be employed.
- Peptides or polypeptides which comprise such peptide fragments may also be employed, with a polypeptide being greater than about 50 amino acids in length, but generally shorter than a full length HBHA protein.
- active peptide fragments may be from about 10 to about 20 amino acids in length.
- the peptides/polypeptides may comprise or may be the 39-amino acid peptide shown below in SEQ ID NO: 5, or sequences with at least about 90% or greater (e.g. 91, 92, 93, 94, 95, 96, 97, 98, or 99%) identity to SEQ ID NO: 5.
- HBHA proteins and fragments thereof that may be used in the practice of the present invention is provided in issued U.S. Pat. No. 6,949,345 (Menozzi et al.), the complete contents of which is hereby incorporated by reference in entirety.
- the Ag85B leader sequence is attached directly to the amino terminus of the HBHA protein by virtue of the two having been translated as a single polypeptide, from tandem nucleic acid sequences within a nucleic acid molecule. In this case, the attachment is covalent and there is no intervening amino acid sequence between the leader sequence and the HBHA sequence.
- relatively short (e.g. from about 1 to about 10) amino acid linker or spacer sequences may be present between the two, e.g. spacers comprising relatively small uncharged amino acids such as glycine, alanine, etc.
- the fusion protein of the invention may have various other modifications, such as the attachment of tagging sequences e.g.
- affinity tags such as His tags, Isopeptag, glutathiono-S-transfcrasc (GST), chitin binding protein (CBP), maltose binding protein (MBP), etc.
- solubilzation tags such as thioredoxin, MBP, GST, etc.
- chromatography tags such as FLAG-tag; epitope tags such as V5-tag, c-myc-tag, HA-tag, etc.; and fluorescent tags such as various green fluorescent protein (GFP) tags and derivatives thereof, etc.
- GFP green fluorescent protein
- the immunogenic recombinant fusion protein sequence of the present invention is methylated, e.g. at the heparin-binding region of the HBHA.
- the methyl groups are carried by lysine residues present in said heparin-binding region.
- the sequence for said carboxy-terminal region is as follows:
- methyl groups are carried by all or only part of the lysine residues present in the C-terminal region of HBHA.
- at least about ten lysine residues e.g. about 10, 11, 12, 13, 14 or 15
- the methylated lysine residues being mono- or di-methylated.
- the fusion protein of the invention may be synthesized chemically, e.g. using methodology that is well known in the art.
- methylation is or may be carried out in vitro, e.g. as described by above-cited Pethe.
- the amino acid sequence of the recombinant fusion protein is: mrrlcaridi wpphtvcsgp strrhtgqrg tsmatdvsrk irawgrrlmi gtaavvlpg Ivglaggaat agafsmaens niddikapll aalgaadlal atvnelitnl reraeetrtd trsrveesra rltklqedlp eqltelrekf taeclrkaae gyleaatsry nelvergeaa lerlrsqqsf eevsaraegy vdqaveltqe algtvasqtr avgeraaklv gielpkkaap akkaapakka apakkaaakk apakkaakk vtqk (S)
- the amino acid sequence of the recombinant fusion protein is a sequence that is at least about 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to that of SEQ ID NO: 3, while still retaining sufficient functionality i.e. antigenicity to elicit an immune response in a subject to, whom it is administered, or still being capable of reacting in assays to detect, e.g. the presence of a latent TB infection in a patient.
- conservative amino acid substitutions may be made in the sequence, whereby amino acids with positively charged side chains are substituted by other amino acids with positively charged side chains (e.g.
- amino acids with negatively charged side chains are substituted by other amino acids with negatively charged side chains (e.g. aspartic acid and glutamic acid); or whereby amino acids with hydrophobic side chains are substituted by other amino acids with hydrophobic side chains (alanine, leucine, etc.); or whereby amino acids with polar uncharged side chains are substituted by other amino acids with polar uncharged side chains (serine, threonine, etc.); and other substitutions that do not negatively impact the antigenicity of the protein.
- certain other mutations to of deletions of or additions of single amino acids or short sequences of amino acids e.g.
- the HBHA protein whose primary amino acid sequence is set forth in SEQ ID NO: 3 was identified in and derived from M. tuberculosis and is a native Mtb sequence. However, those of skill in the art will recognize that other HBHA proteins may also be utilized in the practice of the invention. Generally, the HBHA is identified in or derived from (i.e. is native to) a mycobacterial species or strain, for example, various strains of M. bovis or M. tuberculosis , but may come from any source so long as it functions as described herein, i.e. advantageously large quantities of the protein may be produced as described herein (e.g. at least about 10 to about 300 or more (e.g.
- the antigenic quality of the protein is maintained, i.e. the antigenicity of the protein is comparable to that of the fusion protein represented by SEQ ID NO: 3, in terms of eliciting an immune response.
- Methods of growing bacterial cultures in order to produce protein are well known in the art, as are methods of obtaining, and isolating or purifying proteins produced in this manner.
- the invention encompasses methods of making the fusion protein described herein by transfecting (e.g. by electroporation) a suitable mycobacterial cell, growing the transfected cell under culture conditions which are suitable for the growth of the organism and production of the protein by the organism, and then obtaining and purifying the protein. Exemplary conditions and techniques are described in the Examples section below.
- the nucleic acid that is introduced into the mycobacterial cell is contained within a vector such as a plasmid.
- a vector such as a plasmid.
- other transfectable or transferable vectors may be used in the practice of the invention, e.g. various viral vectors, other episomal elements, etc.
- the nucleic acids sequences of interest may be incorporated into the genome of the mycobacterium.
- the fusion protein that is produced and used in the practice of the present invention is, in some embodiments, substantially purified, e.g. a preparation of the protein is generally (e.g. at least 80, 90, 95, or even 99% or more) free of other proteins, as well as being free of other cellular components, e.g. nucleic acids, lipids, and other macromolecules.
- the rMyc of the invention may be employed as a biosource for rHBHA production and the rHBHA so-produced may be used for any purpose.
- the purpose is to produce therapeutic immune response stimulating formulations of isolated, substantially purified fusion protein, which are discussed below.
- the bacterial cells that are used in the practice of the invention may be any that fulfill the criteria of being suitable for use in a vaccine preparation. e.g. they are attenuated (i.e. decreased in virulence or disease causing capacity; rendered innocuous or incapable of causing symptoms—or causing only minor symptoms—of disease, as is understood in the art); of not displaying antibiotic resistance; and being antigenic.
- the cells are various species or variants of mycobacteria, (e.g. mutant or recombinant forms) of Mycobacterium tuberculosis, Mycotabcterium bovis, Mycobacterium smegmatis , or other mycobacteria, etc.
- the bacterial cell is Mycotabcterium bovis BCG and/or various strains thereof, for example, mutant BCGs selected for a particular property, or recombinant BCGs that have been genetically manipulated.
- Exemplary recombinant BCGs are described, for example, in U.S. Pat. Nos. 7,625,572; 7,666,656; 7,829,104; and 8,043,857; all to Sun et al., the complete contents of each of which are hereby incorporated by reference.
- the BCG may be genetically manipulated to contain and express an endosomolytic protein that is active at neutral pH (e.g.
- Perfringolysin O from Clostridium perfringens may also be auxotrophic and not antibiotic resistant, e.g. auxotrophic for the production of leucine, pantothenate, etc., or double auxotrophs such as leucine-pantothenate auxotrophs, etc.
- the mycobacterial cell expresses a pfo gene.
- Exemplary pfo genes include but are not limited to those of bacteria such as Clostridium perfringens .
- those of skill in the art will recognize that other functionally similar proteins exist which could also be employed in the practice of the invention, either in their wild type form, or after being genetically modified to render them suitable.
- endosomalytic proteins include but are not limited to Listeriolysin (Llo, produced by Listeria monocytogenes ), Pneumolysin (produced by Streptococcus pneumoniae ), Streptolysin O (produced by Streptococcus pyogenes ), Cerolysin (produced by Bacilus cereus ), ⁇ -hemolysin (produced by Staphylococcus aureus ), etc.
- the cell that is employed is a pantothenate auxotroph of a BCG Danish SSI strain expressing a Clostridium perfringens pfo gene, referred to herein as “AERAS-413”.
- mycobactieral strains e.g. other BCG strains such as BCG SSI without the pfo gene, Tokyo, Tice, etc.
- BCG SSI without the pfo gene, Tokyo, Tice, etc.
- BCG SSI without the pfo gene, Tokyo, Tice, etc.
- the antigenically active form of the fusion protein of the invention is methylated.
- methylation is carried out by and within the rMyc cell, which, in some embodiments, has a native, intrinsic capacity to produce active methyltransferase enzymes.
- the cell may be further modified to include nucleic acid sequences expressing additional methyltransferases, or further modified to produce higher levels of native methyltransferases.
- compositions for use in eliciting an immune response against M. tuberculosis and/or vaccinating an individual against tuberculosis include, as an active agent, one or more rMyc species or strains, and a pharmacologically suitable carrier.
- the compositions include, as an active agent, one or more substantially purified fusion proteins as described herein, and a pharmacologically suitable carrier.
- the preparation of such compositions for use as vaccines is well known to those of skill in the art. Typically, such compositions are prepared either as liquid solutions or suspensions, however solid forms such as tablets, pills, powders and the like are also contemplated.
- Solid forms suitable for solution in, or suspension in, liquids prior to administration may also be prepared.
- the preparation may also be emulsified.
- the active ingredients may be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredients. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol and the like, or combinations thereof.
- the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like.
- the composition may contain various adjuvants (compounds that can induce or increase the humoral and/or cellular immune response towards an antigen or immunogen).
- an immunogenic composition of the invention comprises, per dose, from about 0.1 to about 50 ⁇ g of fusion protein, and generally from about 1 to 50 ⁇ g, e.g. about 15 ⁇ g of purified HBHA fusion protein. If the composition of the product comprises a live bacteria (e.g. an attenuated bacteria), the amount of bacteria per dose is generally in the range of from about 1 ⁇ 10 to about 1 ⁇ 10′, and is usually about 1 ⁇ 10 6 .
- compositions (preparations, formulations, etc.) of the invention may be administered by any of the many suitable means which are well known to those of skill in the art, including but not limited to by injection, intradermally, inhalation, orally, intravaginally, intranasally, by ingestion of a food or probiotic product containing the active agent, topically, as eye drops, via sprays, etc.
- the mode of administration is by injection or intradermally.
- the compositions may be administered in conjunction with other treatment modalities such as substances that boost the immune system, various chemotherapeutic agents, other antigenic agents, various adjuvants, and the like.
- the invention also provides methods for eliciting an immune response in a subject in need thereof.
- the method involves, in one embodiment, administering a composition comprising the fusion protein of the invention, and in another embodiment, administering the rMyc of the invention.
- the immune response that is elicited may be one or both of innate and adaptive, and may involve both cell-mediated and humoral responses, for example, the production of antibodies, and/or a B cell and/or T cell response, etc.
- the response may be protective in that a recipient of the vaccine is protected against subsequent challenge with Mtb, thereby preventing the development of a TB infection, either active or latent.
- the immune response may be such that a latent infection does not result, or, if a latent infection is already present, reactivation of the latent infection to active disease may be prevented, or the extent or severity of infection may be lessened.
- the invention also provides diagnostic tests which utilize the fusion protein of the invention.
- the tests are useful for identifying individuals who have a latent tuberculosis infection.
- the tests typically involve exposure of the immune cells or products of immune cells of a subject identified as possibly having latent TB (e.g. due to exposure to the disease, or for some other reason) to the protein and determining whether or not the immune cells or products thereof react to or recognize the fusion protein.
- exposure is carried out by obtaining a biological sample from the subject (e.g. saliva, sputum, blood, plasma, etc.) and exposing the sample to the fusion protein in order to detect, e.g. the presence of anti-HBHA antibodies in the sample.
- the fusion protein is injected intradermally (e.g. in the manner of the Mantoux or other similar tests) and the reaction of the skin to the protein is observed.
- a positive reaction to the test indicates or confirms that the subject may or is likely to have a latent tuberculosis infection.
- the invention provides methods for producing cultures of the rMyc of the invention for use as seed lots.
- methods involving the batch production, purification and testing of the rMyc are encompassed. Such methods generally involve stepping up production of an initial clonal isolate, growing the isolate on a modest scale in media that is free of serum and animal origin protein, and then inoculating a culture of a desired larger volume (repeating this step as necessary until a sufficient volume is attained); and growing the rMyc culture under conditions that allow the rMyc to grow and undergo cell division.
- the rMyc is grown to a density (A 600 ) of from about 4 to about 6, e.g. about 5. Aliquots of the culture are prepared e.g.
- rMyc for commercial purposes, either directly from the culture, or by concentrating the rMyc (e.g. by centrifugation) and resuspending the pellet in a suitable medium.
- the final amount of bacteria in a seed lot culture is generally on the order of from about 4 ⁇ 10 7 to about 6 ⁇ 10 7 .
- Those of skill in the art are familiar with techniques for the long-term maintenance of such cultures, e.g. cryopreservation, lyophilization, etc.
- the rMyc identity and purity may be tested/confirmed by methods known to those of skill in the art, e.g. by sampling the culture and analyzing it for the presence of the nucleic acid which encodes the fusion protein, or by analyzing it for the presence of the fusion protein itself.
- the invention provides methods for producing a recombinant heparin-binding hemagglutinin (rHBHA) protein product.
- the methods comprise the steps of a) growing a culture of recombinant Mycobacteria comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, the fusion sequence being operably linked to a promoter, and obtaining the rHBHA protein from the culture.
- the Mycobacteria may have been genetically engineered to contain and express the nucleic acid fusion sequence. Growth of the culture may be carried out in any suitable manner, e.g. in shake culture, by fermentation, etc., and the culture may be, for example, a batch or continuous culture.
- the production methods typically also include a step of purifying the rHBHA protein.
- Purification of the protein may be carried out by any of the many suitable technologies that are known to those of skill in the art.
- the technology involves the use of one or more physico-chemical purification techniques.
- Exemplary techniques include but are not limited to: chromatography techniques such as ion exchange chromatography, affinity chromatography, size exclusion chromatography, hydrophobic interaction chromatography, etc.; as well as various cell disruption techniques such as high pressure cell disruption, the use of bead beaters, homogenization, sonication, centrifugation, etc. Combinations of these and other techniques may also be employed.
- the methods may also include a step of verifying the identity of the rHBHA protein.
- Those of skill in the art are familiar with suitable techniques for verifying the identity and/or purity of proteins and polypeptides. Exemplary techniques include but are not limited to: electrophoresis, chromatography, mass spectrometry, amino acid sequencing, etc.
- the methods may also include a step of combining purified rHBHA protein with a physiologically acceptable carrier. Suitable physiologically acceptable or compatible carriers are described elsewhere herein.
- the formulated HBHA protein product further comprises one or more other active agents.
- one or more antigens that are not HBHA i.e. a non-HBHA antigen
- Exemplary additional antigens include but are not limited to, for example, those which elicit an immune response against diseases such as diphtheria; pertusis; tetanus; polio, influenza, hepatitis, rotavirus, pneumonia, measles, mumps, rubella, varicella, meningitis, papillomavirus, etc.
- the rHBHA protein product may also include one or more adjuvants and/or one or more immunogenicity enhancers, examples of which include but are not limited to: mineral salts e.g., aluminum hydroxide (“alum”), aluminium phosphate, calcium phosphate; oil emulsions e.g., MF59, a detergent-stabilised oil-in-water emulsion; particulate adjuvants e.g., virosomes, ISCOMS (structured complex of saponins and lipids); microbial derivatives e.g., MPL(TM) (monophosphoryl lipid A), CpG motifs, modified toxins, etc; various plant derivatives e.g., saponins (QS-21); as well as endogenous immunostimulatory adjuvants e.g., cytokines, heat shock proteins (HSPs) and fragments thereof, etc.
- immunogenicity enhancers examples of which include but are not limited to: mineral salts
- a recombinant BCG strain over-expressing HBHA was used because it is a panCD auxotroph and the presence of panCD on the plasmid with the HBHA gene was used for complementation and colony selection in the absence of antibiotic resistance.
- the Mtb sequence for HBHA gene was taken from the Tuberculist website and was synthesized (DNA 2.0) along with the Ag85B promoter and leader peptide in front of the start HBHA codon ( FIGS. 1A, 1B, and 2 ).
- the synthesized fragment was cloned between sites PacI and SpeI in pKAMCB2 vector which is an E. coli -mycobacterial shuttle vector with a kanamycin resistance marker (aph) and a complementing panCD gene operated via the hsp60 promoter ( FIGS. 3A and 3B ).
- This plasmid was used so that it could complement the panCD auxotrophy in AERAS-413 and also maintain the stability of the plasmid in AERAS-413.
- the antibiotic marker was digested out with HpaI enzyme and the construct was self-ligated to make it “antibiotic resistant marker free” ( FIG. 4 ).
- the self-ligated construct was electroporated into AERAS-413 and the recovered colonies were plated onto 7H10-plates without pantothenate supplement and without antibiotics. The colonies were screened for the presence of the antigen, the plasmid backbone and the absence of the kanamycin antibiotic resistance marker.
- Native HBHA has 100% sequence identity in both BCG and Mtb.
- the recombinant HBHA is expressed using Ag85B promoter and Ag85B leader peptide fused to the N-terminus of the protein ( FIGS. 5A, 5B, and 5C ).
- the colonies from AERAS-413 plates transformed with the pKAMCB2 derivative containing the HBHA gene were screened for the presence of the full length Ag85B-HBHA construct in the plasmid.
- the primers used for this PCR were Ag-HBHA.for: GGTCTTCGTCGGCTTGCTTC (SEQ ID NO: 6) and Ag-HBHA.rev: GCTCTGCCAGTGTTACAACC (SEQ ID NO: 7) and the product size of 2.6 kb was expected which is seen in the colony No. 5 ( FIGS. 6A, 6B, and 6C ).
- the same colonies were tested for the presence of the plasmid backbone spanning from the oriM to panCD complementing gene and for the absence of the antibiotic resistance marker.
- Primers used for the plasmid backbone were oriM7932.for GTCTACGAGGCCACACTCAG (SEQ ID NO: 8) and pan9969.rev TATCGCGCAGCTCCAGGTAG (SEQ ID NO: 9).
- Primers used for checking the kanamycin antibiotic marker m the plasmid were kan_intrnl.for GCTCGAGGCCGCGATTAAATTC (SEQ ID NO: 10) and kan_intrnl.rev GGATGGCAAGATCCTGGTATCG (SEQ ID NO: 11).
- Colony No. 5 shows the presence of the plasmid backbone and also the absence of the kanamycin gene from the backbone making it antibiotic marker less.
- the recombinant AERAS-413 strain over-expressing HBHA was named AERAS-445 and was used for further phenotypic analysis and scale-up manufacturing. ( FIGS. 6A, 6B, and 6C )
- AERAS-445 grown under conditions described above was observed to have a similar growth pattern to that of the parent strain AERAS-413 as well as AERAS-401.
- the seed culture was diluted to the OD 600 of 0.2 and the absorbance was measured over 9 days to observe the growth pattern.
- the growth pattern for AERAS-445 was very similar to that of the parent strain indicating that the over-expressed HBHA protein did not have any detrimental effect on the growth kinetics ( FIG. 7 )
- Arrow 1 indicates the recombinant HBHA in AERAS-445 and its absence in the control parent strain AERAS-413 and arrow 2 indicates the native HBHA present in both control AERAS-413 and recombinant AERAS-445.
- the 4057D2 monoclonal antibody which recognizes the methylated portion of the HBHA protein, indicated that the recombinant HBHA produced in AERAS-445 is methylated.
- the Western blot procedure was repeated with the monoclonal antibody 1G10 developed at the Institut Pasteur de Lille, France. AERAS-401 and AERAS-413 was used as controls in this blot.
- Arrow 1 indicates the presence of recombinant HBHA in AERAS-445 and its absence in the control parent strains AERAS-401 and AERAS-413 and arrow 2 indicates the native HBHA is present in both the controls and recombinant strains.
- 1G10 recognizes a specific epitope within the non-methylated region of the HBHA protein ( FIG. 9 ).
- the recombinant BCG was adapted to grow in media free from serum and animal origin protein.
- the final product is a concentrated accession cell bank of 4.5 ⁇ 0.4 mL per vial stored at vapor phase of liquid nitrogen which can be used for the inoculation, e.g. for cGMP Master Cell Bank Production.
- OADC Oleic Albumin Dextrose Catalase
- the culture was centrifuged at 1200 ⁇ g for 30 min at 6 ⁇ 4° C. and re-suspended in 10% GST solution stored at room temperature at 1 ⁇ 4 the original volume (Table 1). The culture was then dispensed in 4.0 ⁇ 0.5 mL aliquots into 5 mL sterile cryovials. The vials were stored in the vapor phase on liquid nitrogen.
- AERAS-445 Two vials of post-freeze AERAS-445 were tested for sterility. The results were negative for any growth contaminants. Vials containing 4 ⁇ concentrated AERAS-445 rBCG were frozen at vapor phase liquid nitrogen. As shown in FIG. 10 , a Western blot with the anti-HBHA monoclonal antibody 1G10 shows the production of the target antigen (HBHA) from cell lysates of AERAS-445 frozen cultures.
- HBHA target antigen
- the filled vials were immediately frozen in vapor phase of liquid nitrogen.
- the amount of HBHA produced in AERAS-445 was estimated by a sandwich ELISA method developed at the Institut Pasteur de Lille.
- the primary monoclonal antibody was 1G10 and the secondary monoclonal antibody was biotinylated 5F2, developed at the Institut Pasteur de Lille (EZ-link Sulfo-NHS-LC-Biotin, Pierce).
- 100 ul per well of mAb 1G10 at 5 ug/ml diluted in coating buffer was seeded on to high affinity binding ELISA plate and incubated over night at 4° C. The plate was washed twice and blocked with PBS-Tween20 (+1% BSA) for 1 hour.
- Recombinant and native HBHA were diluted with 1 ⁇ PBS (8 dilutions) and 100 ul were added onto each well and incubated for 2 hours. After three washes with 1 ⁇ PBS-Tween20, 100 ul of the mAb 5F2 at a concentration of 0.2 ug/ml was added and incubated for 1 hour. The wells were washed thrice and 100 ul Streptavidin-HRP (BD biosciences) conjugate was added at concentration of 1/1000 in PBS and incubated for 30 mins at room temperature. The protein was detected with 100 ul of TMB substrate (ELISA peroxide substrate) and developed at room temperature for 5 mins to 15 mins. The reaction was stopped with 50 ul of 3M H 3 PO 4 and the optical density was read at 450 nm. From this result AERAS-445 expressed almost 8-fold more HBHA compared to the parent strain ( FIGS. 11A and 11B ).
- the yield of HBHA from the M. bovis BCG Pasteur 1173P2 was also compared with AERAS 445.
- the BCG strains were grown in 200 ml agitated Sauton medium in 1-liter flasks for 10 days until the optical density reading at 600 nm reached approximately 1.5.
- the BCG cells were then harvested by centrifugation at 8,500 rpm (Beckmann J2MC centrifuge, rotor JA 0).
- the BCG pellet was then suspended in 20 ml PBS+0.05% Tween 80 (Tw 80: Sigma Ultra, ref P8074) and centrifuged at 6,500 rpm (Beckman Coulter Allegra 64R, rotor F0650) for 20 min at 4° C.
- the pellet was the weighted before suspension in 20 ml PBS+0.05% Tween 80, heat inactivated and sonicated as described below.
- the supernatant of the sonicate was then analyzed for its protein content and for the concentration of HBHA by using the Sandwich ELISA with the monoclonal antibodies 1G10 and 5F2, as described above.
- Pellets of AERAS 445 were resuspended in 20 ml PBS+0.05% Tween80 (Tw 80, Sigma Ultra, ref. P8074) and centrifuged at 6,500 rpm (Beckman Coulter Allegra 64R, rotor F0650) for 20 min. at 4° C.
- the pellets were weighted and resuspended in 20 ml PBS+0.05% Tween 80, heated for 30 min. at 80° C. and centrifuged for 20 min. at 12,000 rpm (Beckman Coulter Allegra 64R, rotor F0650) at 4° C.
- the column was then washed with 100 ml DPBS, and the bound material was eluted by a 0-500 mM NaCl gradient in 100 ml DPBS.
- the eluted 1-ml fractions were identified by SDS-PAGE using a 12% gel followed by Coomassie Brilliant Blue R-250 staining.
- HBHA-containing fractions were pooled and applied onto a reverse-phase HPLC Nucleosil C18 column (TSK gel super ODS; Interchim) equilibrated in 0, 05% trifluoroacetic acid. Bound material was eluted with a linear 0-80% acetonitrile gradient. HBHA-containing fractions were pooled, and the solvent was eliminated by evaporation. The pH of the final fraction of 1 ml was adjusted to pH8 by using 1 M Tris-HCl (pH9). The final product was stored at ⁇ 80° C. HBHA-containing fractions were analyzed by SDS-PAGE, mass spectrometry and sandwich ELISA using the 1G10 and the 5F2 monoclonal antibodies, as described above.
- FIG. 12 shows a mass-spectrometry analysis of purified rHBHA from AERAS 445.
- the protein 0.1 to 10 pmol
- the protein solution 0.5 ⁇ l
- the protein solution was mixed with freshly dissolved a-cyano4-hydroxycinnaminic acid at 10 mg/ml in 50% CH 3 CN and 0.1% trifluoroacetic acid.
- mass spectrometry analysis was performed by using a matrix-assisted laser desorption ionization/time-of-flight (Voyager-DE-STR, Applied Biosystems).
- the following setting parameters were used: positive and linear modes, acceleration voltage of 25 kV, grid voltage of 92%, 750 ns of delayed extraction time, and low mass gate of 1,000 Da.
- the spectra were calibrated externally by using the [M+H+] monoisotopic ions of different peptides for average masses of E. coli thioredoxin and horse apomyoglobin (Applied Riosystems).
- rHBHA Purified rHBHA was digested overnight with 5% endoproteinase Glu-C(Roche), and the resulting peptides were separated by reverse-phase HPLC using a Beckman Ultra sphere ODS column (2 ⁇ 200 mm) and a linear 0-60% acetonitrile elution gradient prepared in 0.1% trifluoroacetic acid and directly analyzed by mass spectrometry.
- the peptide solution was mixed with freshly dissolved a-cyano4-hydroxycinnaminic acid at 10 mg/ml in 50% CH 3 CN and 0.1% trifluoroacetic acid. After spotting and drying, mass spectrometry analysis was performed by using a matrix-assisted laser desorption ionization/time-of-flight Voyager-DE-STR (Applied Biosystems). For peptides between 3,000 Da to 10,000 Da, the following setting parameters were used: positive and reflector modes, acceleration voltage of 25 kV, grid voltage of 65%, 250 ns of delayed extraction, and low mass gate of 1,000 Da. The spectra were calibrated externally by using the [M+H+] monoisotopic ions of different peptides for average masses of E. coli thioredoxin and horse apomyoglobin (Applied Biosystems).
- results of the mass spectrometry analysis of rHBHA purified from AERAS 445 are depicted in FIG. 13 and indicate that the C-terminal end of the protein shows heterogeneity, consistent with the complex methylation profile expected for HBHA.
- the concentration of purified rHBHA from AERAS 445 was measured and adjusted in order to coat overnight at 4° C. 1 ⁇ g per well of ELISA plates.
- the plates were then washed with phosphate buffered saline (PBS)/Tween (PBST), followed by blocking for 2 hrs at room temperature with PBST containing 3% BSA. After washing again three times with PBST, the plates were incubated for 1 h30 at room temperature with serial four-fold dilutions of monoclonal antibodies 3921E4 or 4057D2 in PBST+BSA. The latter two preferentially recognize the methylated forms of HBHA (3).
- FIGS. 14A and 14B show that rHBHA from AERAS 445 is recognized by both the 4057D2 and the 3921E4 monoclonal antibodies, confirming that it is properly methylated.
- rHBHA from AERAS 445 was incubated at 2 g/ml with 10 6 peripheral blood mononuclear cells (PBMC) isolated from three latently infected human subjects, three patients with active tuberculosis and from three negative control subjects. After 96-hours, the IFN- ⁇ concentrations released in the supernatants were measured by ELISA, and the IFN- ⁇ secretion from unstimulated PBMC was subtracted from the antigen-induced IFN- ⁇ secretion. The sensitivity of the IFN- ⁇ (ELISA was 10 ⁇ g/ml. The cut-off value for optimal discrimination between non-infected controls and LTBI subjects was previously determined to be 100 pg/ml for HBHA (4).
- PBMC peripheral blood mononuclear cells
- rHBHA purified from AERAS 445 is well recognized by the PBMCs from latently infected individuals, poorly recognized by the PBMCs from tuberculosis patients and not recognized by the PBMCs from healthy controls.
- HBHA Human T cell antigenicity of HBHA.
- the PBMC from 9 human subjects (3 latently infected subjects Nos. 1, 8 and 9; three active tuberculosis patients Nos. 2, 3 and 4 and 3 negative controls Nos. 5, 6 and 7) were incubated with 2 ⁇ g/ml of HBHA from M. bovis BCG Pasteur 1173P3 (IPL) or AERAS 445 (Aeras).
- HBHAIPL HBHAAeras Patient Number (BCG Pasteur) (AERAS-445) 1 5.21 13.53 2 0.09 0.02 3 0.02 0.11 4 0.24 0.27 5 0.07 0.12 6 ⁇ 0.01 ⁇ 0.01 7 ⁇ 0.01 ⁇ 0.01 8 1.43 .73 9 1.62 1.28
Abstract
Description
- The invention generally relates to recombinant Mycobacteria which contain and express sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein. The fusion protein contains an amino terminal mycobacterial antigen Ag85B leader sequence, and transcription of the fusion protein is driven by a suitable promoter, e.g. the Ag85B promoter. The invention also provides methods of making and using the recombinant Mycobacteria and the recombinant fusion protein, e.g. as vaccinogens.
- Tuberculosis (TB) is a global public health problem resulting in 8 million new cases and 2 million deaths each year. A particularly problematic aspect of TB diagnosis and treatment is the ability of the Mycobacterium tuberculosis (Mtb) bacillus to enter a latent, asymptomatic state and to persist in latently infected individuals for long periods of time. Such individuals are susceptible to reactivation of the disease due to, for example, immune suppression caused by diseases or conditions such as HIV, treatments such as chemotherapy and the use of corticosteroids, the waning of immunity that accompanies aging, etc. An estimated 2 billion persons (one-third of the world's population) are latently infected with Mtb at present, and activation of latent tuberculosis accounts for most new cases of active disease. Reactivation is associated with inflammation, necrosis and cavitation of the lung, a process that results in draining of the lesions into the bronchus. Aerosols generated when individuals with bronchial lesions cough causes dissemination of the Mtb organism to uninfected, susceptible persons, and the transmission cycle is thus maintained.
- The only currently available vaccine against TB, Mycobacterium bovis (Bacille Calmette-Guérin) (BCG), was first introduced in 1921. BCG has been widely utilized and while studies show that for some purposes BCG is effective (e.g. against disseminated TB), it is known to be ineffective with respect to preventing the development, persistence and reactivation of latent TB.
- There is an ongoing need to develop improved, more effective vaccines against TB. In particular, there is a need to develop vaccines that provide protection against the development, maintenance and/or reactivation of latent tuberculosis infection.
- One protein that has been proposed for use in TB vaccines is the heparin-binding hemagglutinin (HBHA) protein. HBHA is a 22-kDa, methylated, surface-exposed protein that mediates the interaction of the tubercle bacilli with the host, acting as an adhesin for nonphagocytic cells. Methylation of the C-terminal lysine residues is known to affect both the biochemical and immunological properties of the protein, and several experimental findings have implicated HBHA in the process of extrapulmonary dissemination of Mtb (Pethe et al., 2001. Nature 412:190-194.). Temmerman et al. (Nature Medicine 10, 935-941 (2004)) showed that covalent methylation of HBHA is necessary for the elicitation of a protective T cell response in mice challenged with Mtb, and Zannetti et al. showed that purified methylated HBHA is strongly recognized by sera obtained from TB patients compared to controls, whereas unmethylated HBHA is not (Clin Diagn Lab Immunol September 2005 vol. 12 no. 9 1135-1138). In light of these and other studies, it has been proposed that the development of an HBHA-based vaccine may represent an effective strategy to prevent and/or treat TB.
- U.S. Pat. No. 7,829,103 to Pethe et al., the complete contents of which is hereby incorporated by reference in entirety, reports immunogenic compositions comprising methylated recombinant HBHA. According to Pethc, the HBHA may be produced by one of two methods: either by 1) producing recombinant non-methylated HBHA protein in a heterologous cell (Escherichia coli or Mycobacterium smegmatis) and then post-translationally methylating the purified recombinant HBHA using a chemical or enzymatic method; or 2) using a recombinant cell to co-express nucleotide sequences encoding HBHA and a mycobacterial methyltransferase.
Method 1 involves multiple steps for protein preparation;method 2 involves the use of a heterologous cell that is not administrable as a vaccine. Further, the bacterial strains employed by Pethe were antibiotic resistant, and no discussion of optimizing protein yields is provided. Thus, there remains a need in the art for a recombinant Mtb that is capable of being used as a vaccinogen, and/or for producing sufficient quantities of HBHA to be clinically relevant, both in vitro and in vivo, and/or for producing large quantities of HBHA in a manufacturing setting for later use in clinical applications. - The invention provides recombinant Mycobacteria (rMyc) which contain and express nucleic acid sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein. The fusion protein includes a mycobacterial antigen Ag85B leader peptide attached at the amino terminus. The fusion protein is post-translationally methylated, resulting in a protein with a methylation pattern that is the same as or highly similar to that of native HBHA. The resulting fusion protein is thus highly antigenic, and copious amounts of the highly antigenic fusion protein can be produced using the methods of the invention. Transcription of the fusion protein is driven by a suitable promoter, which can be constitutive or inducible. In one embodiment, the promoter is the Ag85B promoter sequence, The invention also provides methods of making the rMyc (e.g. on an industrial scale), methods of using the rMyc e.g. as a vaccinogen and/or to elicit an immune response, or to make the fusion protein; or to produce seed cultures; and methods of making and using the fusion protein e.g. as a vaccinogen and/or to elicit an immune response, or as a diagnostic, for example, to detect latent tuberculosis infections.
- It is an object of this invention to provide a recombinant Mycobacterium that is genetically engineered to contain and express a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, the fusion sequence being operably linked to a promoter. In some embodiments, the Mycobacterium is, for example, Mycobacterium tuberculaosis, Mycobacterium bovis, or Mycobacterium smegmatis. In other embodiments, the Mycobacterium is Mycobacterium bovis e.g. Mycobacterium bovis (Bacille Calmette-Guérin) (BCG). In some embodiments, the BCG is a BCG Danish Statens Serum Institut (SSI) strain and may, for example, express a pfo gene such as a pfo gene from Clostridium perfringens. In some embodiments, the Mycobacterium is an auxotroph, for example, a pantothenic acid auxotroph.
- In some embodiments of the invention, the nucleic acid fusion sequence is
-
(SEQ ID NO: 1) atgagacgac tttgcgcccg aatcgacatt tggcctccac acacggtatg ttctggcccg agcacacgac gacatacagg acaaaggggc acaagtatgg ccacagacgt gagccgaaag attcgagctt ggggacgccg attgatgatc ggcacggcag cggctgtagt ccttccgggc ctggtggggc ttgccggcgg agcggcaacc gcgggcgcgt tctccatggc tgaaaactcg aacattgatg acatcaaggc tccgttgctt gccgcgcttg gagcggccga cctggccttg gccactgtca acgagttgat cacgaacctg cgtgagcgtg cggaggagac tcgtacggac acccgcagcc gggtcgagga gagccgtgct cgcctgacca agctgcagga agatctgccc gagcagctca ccgagctgcg tgagaagttc accgccgagg agctgcgtaa ggccgccgag ggctacctcg aggccgcgac tagccggtac aacgagctgg tcgagcgcgg tgaggccgct ctagagcggc tgcgcagcca gcagagcttc gaggaagtgt cggcgcgcgc cgaaggctac gtggaccagg cggtggagtt gacccaggag gcgttgggta cggtcgcatc gcagacccgc gcggtcggtg agcgtgccgc caagctggtc ggcatcgagc tgcctaagaa ggctgctccg gccaagaagg ccgctccggc caagaaggcc gctccggcca agaaggcggc ggccaagaag gcgcccgcga agaaggcggc ggccaagaag gtcacccaga agtag. - In other embodiments, the polypeptide encoded by the nucleic acid fusion sequence has an amino acid sequence: mrrlcaridi wpphtvcsgp strrhtgqrg tsmatdvsrk irawgrrlmi gtaaavvlpg lvglaggaat agafsmaens niddikapll aalgaadlal atvnelitnl reraeetrtd trsrveesra rltklqedlp eqltelrekf taeelrkaae gyleaatsry nelvergeaa lerlrsqqsf eevsaraegy vdqaveltqe algtvasqtr avgeraaklv gielpkkaap akkaapakka apakkaaakk apakkaaakk vtqk (SEQ ID NO: 3).
- In some embodiments, the mycobacterial HBHA protein is Mycobacterium tuberculosis HBHA. In yet other embodiments, the promoter is a mycobacterial Ag85B promoter
- The invention also provides an isolated recombinant nucleic acid molecule with a nucleotide sequence:
-
(SEQ ID NO: 1) atgagacgac tttgcgcccg aatcgacatt tggcctccac acacggtatg ttctggcccg agcacacgac gacatacagg acaaaggggc acaagtatgg ccacagacgt gagccgaaag attcgagctt ggggacgccg attgatgatc ggcacggcag cggctgtagt ccttccgggc ctggtggggc ttgccggcgg agcggcaacc gcgggcgcgt tctccatggc tgaaaactcg aacattgatg acatcaaggc tccgttgctt gccgcgcttg gagcggccga cctggccttg gccactgtca acgagttgat cacgaacctg cgtgagcgtg cggaggagac tcgtacggac acccgcagcc gggtcgagga gagccgtgct cgcctgacca agctgcagga agatctgccc gagcagctca ccgagctgcg tgagaagttc accgccgagg agctgcgtaa ggccgccgag ggctacctcg aggccgcgac tagccggtac aacgagctgg tcgagcgcgg tgaggccgct ctagagcggc tgcgcagcca gcagagcttc gaggaagtgt cggcgcgcgc cgaaggctac gtggaccagg cggtggagtt gacccaggag gcgttgggta cggtcgcatc gcagacccgc gcggtcggtg agcgtgccgc caagctggtc ggcatcgagc tgcctaagaa ggctgctccg gccaagaagg ccgctccggc caagaaggcc gctccggcca agaaggcggc ggccaagaag gcgcccgcga agaaggcggc ggccaagaag gtcacccaga agtag. - The invention also provides a recombinant fusion protein which comprises an Ag85B leader sequence covalently attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein. In one embodiment, the entire fusion protein is transcribed as one mRNA and translated as a single polypeptide (protein). In one embodiment, the recombinant fusion protein has an amino acid sequence: mrrlcaridi wpphtvcsgp strrhtgqrg tsmatdvsrk irawgrrlmi gtaaavvlpg lvglaggaat agafsmaens niddikapll aalgaadlal atvnelitnl reracetrtd trsrveesra rltklqedlp eqltelrekf taeclrkaae gyleaatsry nelvergeaa lerlrsqqsf ccvsaraegy vdqavcltqec algtvasqtr avgeraaklv gielpkkaap akkaapakka apakkaaakk apakkaaakk vtqk (SEQ ID NO: 3). In some embodiments, the recombinant fusion protein is methylated.
- The invention also provides methods of producing a recombinant fusion protein that comprises an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein. The method comprises: 1) transfecting a bacterial cell such as a Mycobacterium cell with a nucleic acid sequence encoding the recombinant fusion protein; 2) growing the transfected bacterium (e.g. a Mycobacterium) cell under conditions which allow the bacterium cell to produce the recombinant fusion protein; and 3) obtaining the recombinant fusion protein. In some embodiments, the transfecting is carried out by electroporation.
- The invention also provides methods of determining whether a subject has a latent tuberculosis infection. The method comprises determining the presence or absence of immune reactivity of the patient to a recombinant fusion protein comprising an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein. The presence of immune reactivity indicates that the subject has a latent tuberculosis infection. Determining the presence or absence of immune reactivity may include, for example, 1) obtaining a biological sample from the subject, and 2) detecting the presence or absence of immune reactivity in the biological sample. Exemplary biological samples include but are not limited to sputum samples and serum samples. In other embodiments, determining the presence or absence of immune reactivity may include the step of detecting includes 1) intradermally injecting the recombinant fusion protein into the subject, and 2) determining the presence or absence of immune reactivity at the site of intradermal injection.
- The invention also provides methods of eliciting an immune response against Mycobacterium tuberculosis in a subject in need thereof. This method comprises the step of administering to the subject an amount of a recombinant fusion protein comprising an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein sufficient to elicit an immune response in said subject, and may be referred to as a “therapeutic” amount. In one embodiment, the immune response that is elicited is production of one or more of B cells, antibodies and T cells. In some embodiments, the immune response is a protective immune response.
- The invention also provides methods of eliciting an immune response against Mycobacterium tuberculosis in a subject in need thereof. The method comprises administering to the subject a recombinant Mycobacterium comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein. The fusion sequence is operably linked to a promoter, and the recombinant Mycobacterium is administered in an amount sufficient to elicit an immune response in the subject. In one embodiment, the immune response is production of antibodies. In some embodiments, the immune response is a protective immune response.
- The invention also provides methods of producing recombinant heparin-binding hemagglutinin (rHBHA) protein. The methods comprise 1) growing a culture of recombinant Mycobacteria comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, wherein said fusion sequence is operably linked to a promoter, under conditions in which the rHBHA is produced. In some embodiments, the method further comprises obtaining the rHBHA protein from the culture. The method may also include purifying the rHBHA protein, e.g. after the step of obtaining the rHBHA. Purifying may be carried out using one or more physico-chemical technologies such as, for example, chromatography (e.g. one or more of affinity, size exclusion, ion exchange, or hydrophobic interaction chromatography); and/or cell disruption techniques (e.g. one or more of high pressure cell disruption, bead beaters, homogenization, sonication, centrifugation, and the like). The method may also include verifying the identity of the rHBHA protein. In some embodiments, the step of growing is carried out in culture by shaking or by fermentation. In some embodiments, growing is carried out using a hatch or a continuous culture.
- The invention further provides seed lots of recombinant Mycobacterium. In some embodiments, a seed lot comprises 1) recombinant Mycobacteria comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, wherein the fusion sequence is operably linked to a promoter; and 2) medium suitable for maintaining the recombinant Mycobacteria in a viable state during storage of the seed lot.
- The invention also provides methods of preparing a composition comprising a heparin-binding hemagglutinin (HBHA) protein. In some embodiments, the method comprises 1) growing a culture of recombinant Mycobacteria comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, wherein the fusion sequence is operably linked to a promoter; 2) obtaining the rHBHA protein from the culture; 3) purifying the rHBHA protein; and 4) combining purified rHBHA protein with a physiologically acceptable carrier. The growing may be carried out in shake culture or by fermentation. In addition, method may further comprise adding one or more additional therapeutically useful agents, including but not limited to, one or more antigens that are not HBHA, one or more adjuvants, and one or more immunogenicity enhancers, to the rHBHA and physiologically acceptable carrier. These compositions may be used, for example, as a vaccine, a therapeutic or a diagnostic, or for any other purpose.
-
FIG. 1A shows the DNA sequence (SEQ ID NO:1) encoding the HBHA fusion protein. The Ag85B leader peptide is encoded by the underlined nucleotides.FIG. 1B shows the DNA sequence encoding the HBHA fusion protein as inFIG. 1A but also shows the exemplary Ag85B promoter sequence in bold (SEQ ID NO: 2). -
FIG. 2 shows the in silico cloning and complementation strategy. -
FIG. 3A shows the schematic of the pantothenate complementation plasmid (pKAMCB2) andFIG. 3B shows the cloning of HBHA gene into pKAMCB2. -
FIG. 4 shows the schematic unmarking of the pKAMCB2+HBHA clone for kanamycin resistance. -
FIG. 5A shows the amino acid sequence of recombinant HBHA (SEQ ID NO: 3) compared withFIG. 5B , which shows the native HBHA from which amino terminal methionine has been cleaved (SEQ ID NO: 4) andFIG. 5C , which shows the schematic position of the Ag85B leader at the N-terminus. -
FIG. 6A shows the recombinant BCG colonies PCR screened for the HBHA gene.FIG. 6B shows the presence of plasmid backbone andFIG. 6C shows the absence of the kanamycin resistance marker. Clone no. 5 tested positive for the presence of HBHA gene, intact plasmid backbone and the absence of kanamycin gene. -
FIG. 7 shows the growth kinetics ofAERAS 445, a pantothenate auxotroph of a BCG Danish SSI strain expression a Clostridium perfringens pfo gene, and further modified to encode the HBHA fusion protein of the invention. -
FIG. 8 shows the Western blot over expression of HBHA in AERAS-445 using 4057D2 anti-HBHA monoclonal antibody.Arrows -
FIG. 9 shows the Western blot over expression of HBHA in AERAS-445 using 1G10 antibody. Lanes: 1 AERAS-401; 2 AERAS-413; 3AERAS 445.Arrows -
FIG. 10 shows the Western blot HBHA expression using 1G10 antibody in different stages of manufacturing AERAS-445.Arrows AERAS 413; 2Stage 2 manufacturing sample; 3 Accession Fermentor sample.Arrows -
FIGS. 11A and 11B show the yields of HBHA protein in strains determined by sandwich ELISA;FIG. 11A , depicted graphically, andFIG. 11B , depicted as a bar graph. -
FIG. 12 shows the mass spectrometry analysis of rHBHA purified fromAERAS 445. -
FIG. 13 shows the mass-spectrometry analysis of the C-terminal end of rHBHA purified fromAERAS 445. -
FIGS. 14A and 14B show the antigenicity analysis by ELISA using monoclonal antibodies 3921E4 (FIG. 14A ): and 4057D2 (FIG. 14B ). - In one embodiment, the invention provides recombinant Mycobacteria (rMyc) which contain and express nucleic acid sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein. The recombinant Mycobacteria can be administered in vaccine preparations since they are not antibiotic resistant and are attenuated. The fusion protein includes, attached to its amino terminus, a mycobacterial antigen Ag85B leader peptide sequence. The rMycs of the invention produce large amounts of the fusion protein, with transcription being driven by a suitable promoter. The fusion protein may also be recovered from the rMyc in an industrial manufacturing process and be used as part of a vaccine preparation or diagnostic.
- In one embodiment, the nucleic acid sequence that encodes the antigenic recombinant fusion protein of the invention is the DNA sequence depicted in
FIG. 1A (SEQ ID NO: 1) As can be seen, the nucleic acid encodes the Ag85B leader sequence atnucleotides 1 to 225 (underlined) and the HBHA protein at nucleotides 226 to 825. In addition, in the exemplary embodiment depicted inFIG. 1B , at its 5′ end, the nucleic acid contains the Ag85B promoter sequence atnucleotides 1 to 184 (shown in bold). In the embodiment illustrated inFIG. 1B , the translated fusion protein per se that is produced by the cell is thus encoded by nucleotides 185 to 1009, i.e. the promoter region is not translated. - In one embodiment, the invention encompasses a nucleic acid with a sequence which is or which includes the sequence as set forth in SEQ ID NO: 1 (see
FIG. 1A ). In another embodiment, the invention encompasses a nucleic acid with a sequence that is or includes the sequence as set forth in SEQ ID NO: 2 (secFIG. 1B ). In another embodiment, the invention encompasses a nucleic acid with a sequence that is or includes the sequence as set forth in SEQ ID NO: 3 (see below). The invention also encompasses DNA that is complementary to SEQ ID NOS: 1 and 2, and also mRNA that is translated from SEQ ID NOS: 1 and 2 (or complements thereof), or cDNA based on such mRNA (as well as various DNA-RNA hybrids of these), and encompasses both single and double stranded nucleic acids. Further, those of skill in the art will recognize that, in order to produce an antigenic recombinant fusion protein as described herein (i.e. comprising an Ag85B leader sequence attached to an amino terminus of a mycobacterial HBHA protein), the precise sequence of SEQ ID NOS: 1 and 2 need not be employed. For example, sequences with at least about 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, or about 99% homology to SEQ ID NOS: 1 and 2 may also be employed, so long as the translated polypeptide is able to be methylated and is sufficiently antigenic to elicit an immune response in a subject to whom it is administered. These levels of homology are also applicable to the corresponding complementary DNA, RNA, etc. described above. Those of skill in the art are familiar with automated programs or software for determining homology levels. In addition, those of skill in the art will recognize that the nucleic acid sequence that encodes the fusion protein may also include various helpful sequences, e.g. restriction sites for ease of genetic manipulation of the sequence. The % homologies described herein can be determined, for example, using the Smith-Waterman homology search algorithm as implemented in MSPRCH program (Oxford Molecular) using anaffine gap search with the following search parameters: gap open penalty of 12, and gap extension penalty of 1. - Exemplary variations of the recombinant sequence include but are not limited to: the substitution of codons which encode conservative amino acid replacements of some encoded residues; the insertion of e.g. sequences encoding linker or spacer sequences, e.g. between the promoter and the leader sequence, or between the leader sequence and the HBHA encoding sequence; various changes to the sequence to facilitate handling or manipulation of the sequence, e.g. the insertion of or change in restriction enzyme sites which flank the sequence; portions of a vector (e.g. 5′ or 3′ overhangs or sequences complementary to the same), sequences which encode various tags as described below, etc. This is illustrated in the sequence of SEQ ID NO: 3, where additional non-coding sequences at the 5′ and 3′ ends of the sequence are shown in italics, and the bold and underlined sequences represent promoter region and a leader peptide, as described above.
-
(SEQ ID NO: 12) ACTGTTAATTAA GTGGTCTTCGTCGGCTTGCTTCGAGCGAGCCTACGCG GTGAACGCAAGTTCGGCCTCCCTGGGGGAGCACAGCCGGTAGCCCCGGG CCGCGATTCTGAGAA ATCCGCGATAGATCCATACCGCCATACCGTTTGT GAGCCCCCTAAGCACACTTGCTCTGTCCGCGGCGGTAACCGATACGGAA ATGAGACGACTTTGCGCCCGAATCGACATTTGGCCTCCACACACGGTAT GTTCTGGCCCGAGCACACGACGACATACAGGACAAAGGGGCACAAGTAT GGCCACAGACGTGAGCCGAAAGATTCGAGCTTGGGGACGCCGATTGATG ATCGGCACGGCAGCGGCTGTAGTCCTTCCGGGCCTGGTGGGGCTTGCCG GCGGAGCGGCAACCGCGGGCGCGTTCTCCATGGCTGAAAACTCGAACAT TGATGACATCAAGGCTCCGTTGCTTGCCGCGCTTGGAGCGGCCGACCTG GCCTTGGCCACTGTCAACGAGTTGATCACGAACCTGCGTGAGCGTGCGG AGGAGACTCGTACGGACACCCGCAGCCGGGTCGAGGAGAGCCGTGCTCG CCTGACCAAGCTGCAGGAAGATCTGCCCGAGCAGCTCACCGAGCTGCGT GAGAAGTTCACCGCCGAGGAGCTGCTGTAAGGCCGCCGAGGGCTACCTC GAGGCCGCGACTAGCCGGTACAACGAGCTGGTCGAGCGCGGTGAGGCCG CTCTAGAGCGGCTGCGCAGCCAGCAGAGCTTCGAGGAAGTGTCGGCGCG CGCCGAAGGCTACGTGGACCAGGCGGTGGAGTTGACCCAGGAGGCGTTG GGTACGGTCGCATCGCAGACCCGCGCGGTCGGTGAGCGTGCCGCCAAGC TGGTCGGCATCGAGCTGCCTAAGAAGGCTGCTCCGGCCAAGAAGGCCGC TCCGGCCAAGAAGGCCGCTCCGGCCAAGAAGGCGGCGGCCAAGAAGGCG CCCGCGAAGAAGGCGGCGGCCAAGAAGGTCACCCAGAAGTAGACTAGTT CAT. - Expression of the fusion protein is driven by a promoter sequence that is operably linked to SEQ ID NO: 1. By “operably linked” it is meant that the promoter sequence and SEQ ID NO: 1 are arranged within a nucleic acid molecule such that expression of SEQ ID NO: 1 is driven or controlled by the promoter. In some embodiments, the promoter may directly precede SEQ ID NO: 1 in the molecule. In other embodiments, some additional sequences may intervene. In addition, other control elements that aid in expression of SEQ ID NO: 1 may also be included in the nucleic acid molecule, e.g. various enhancer sequences, etc. Exemplary promoters that may be used in the practice of the invention include but are not limited to, for example, promoters of genes hsp60, hspX, pBlaF or mtrA, etc. In one embodiment, the promoter is the Ag85B promoter, and is arranged with respect to SEQ ID NO: 1 as is depicted in
FIG. 1B (the sequence in bold), i.e. is placed directly upstream of SEQ ID NO: 1. - The fusion protein of the invention, as translated, is an antigenic recombinant fusion or chimeric protein (polypeptide) which comprises: 1) a mycobacterial HBHA protein sequence, or a functional portion thereof; and 2) an Ag85B leader peptide (or functional portion thereof) attached to or associated with the amino terminus of the HBHA protein. By “a mycobacterial HBHA protein sequence or functional portion thereof” we mean an HBHA protein with a sequence as depicted in
FIG. 5B (SEQ ID NO: 4) or peptide or polypeptide fragments thereof which are antigenic, i.e. which elicit the production of antibodies which bind to native HBHA, when administered as a component of the fusion protein of the invention. Such fragments may also be sufficient to interact with and bind to heparin. For example, antigenic peptide fragments of about 50 amino acids or less in length which are comprised within about the last 30 to 50 amino acids located at the carboxyl terminus of SEQ ID NO: 4 may be employed. Peptides or polypeptides which comprise such peptide fragments may also be employed, with a polypeptide being greater than about 50 amino acids in length, but generally shorter than a full length HBHA protein. In some embodiments, such active peptide fragments may be from about 10 to about 20 amino acids in length. In other embodiments, the peptides/polypeptides may comprise or may be the 39-amino acid peptide shown below in SEQ ID NO: 5, or sequences with at least about 90% or greater (e.g. 91, 92, 93, 94, 95, 96, 97, 98, or 99%) identity to SEQ ID NO: 5. Further description of HBHA proteins and fragments thereof that may be used in the practice of the present invention is provided in issued U.S. Pat. No. 6,949,345 (Menozzi et al.), the complete contents of which is hereby incorporated by reference in entirety. - In some embodiments, the Ag85B leader sequence is attached directly to the amino terminus of the HBHA protein by virtue of the two having been translated as a single polypeptide, from tandem nucleic acid sequences within a nucleic acid molecule. In this case, the attachment is covalent and there is no intervening amino acid sequence between the leader sequence and the HBHA sequence. However, in some embodiments, relatively short (e.g. from about 1 to about 10) amino acid linker or spacer sequences may be present between the two, e.g. spacers comprising relatively small uncharged amino acids such as glycine, alanine, etc. In addition, in some embodiments, the fusion protein of the invention may have various other modifications, such as the attachment of tagging sequences e.g. to facilitate isolation or detection, e.g. affinity tags such as His tags, Isopeptag, glutathiono-S-transfcrasc (GST), chitin binding protein (CBP), maltose binding protein (MBP), etc.; solubilzation tags such as thioredoxin, MBP, GST, etc.; chromatography tags such as FLAG-tag; epitope tags such as V5-tag, c-myc-tag, HA-tag, etc.; and fluorescent tags such as various green fluorescent protein (GFP) tags and derivatives thereof, etc.
- The immunogenic recombinant fusion protein sequence of the present invention is methylated, e.g. at the heparin-binding region of the HBHA. In particular, the methyl groups are carried by lysine residues present in said heparin-binding region. The sequence for said carboxy-terminal region is as follows:
-
(SEQ ID NO: 5) KKAAPAKKAAPAKKAAPAKKAAAKKAPAKKAAAKKVTQK
The methyl groups are carried by all or only part of the lysine residues present in the C-terminal region of HBHA. Advantageously, at least about ten lysine residues (e.g. about 10, 11, 12, 13, 14 or 15) out of the fifteen present in the C-terminal region are methylated, with the methylated lysine residues being mono- or di-methylated. - In alternative embodiments, the fusion protein of the invention may be synthesized chemically, e.g. using methodology that is well known in the art. In this embodiment, methylation is or may be carried out in vitro, e.g. as described by above-cited Pethe.
- In one embodiment of the invention, the amino acid sequence of the recombinant fusion protein is: mrrlcaridi wpphtvcsgp strrhtgqrg tsmatdvsrk irawgrrlmi gtaaavvlpg Ivglaggaat agafsmaens niddikapll aalgaadlal atvnelitnl reraeetrtd trsrveesra rltklqedlp eqltelrekf taeclrkaae gyleaatsry nelvergeaa lerlrsqqsf eevsaraegy vdqaveltqe algtvasqtr avgeraaklv gielpkkaap akkaapakka apakkaaakk apakkaaakk vtqk (SEQ ID NO: 3). In other embodiments, the amino acid sequence of the recombinant fusion protein is a sequence that is at least about 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to that of SEQ ID NO: 3, while still retaining sufficient functionality i.e. antigenicity to elicit an immune response in a subject to, whom it is administered, or still being capable of reacting in assays to detect, e.g. the presence of a latent TB infection in a patient. For example, conservative amino acid substitutions may be made in the sequence, whereby amino acids with positively charged side chains are substituted by other amino acids with positively charged side chains (e.g. lysine, histidine, arginine); or whereby amino acids with negatively charged side chains are substituted by other amino acids with negatively charged side chains (e.g. aspartic acid and glutamic acid); or whereby amino acids with hydrophobic side chains are substituted by other amino acids with hydrophobic side chains (alanine, leucine, etc.); or whereby amino acids with polar uncharged side chains are substituted by other amino acids with polar uncharged side chains (serine, threonine, etc.); and other substitutions that do not negatively impact the antigenicity of the protein. Further, certain other mutations to of deletions of or additions of single amino acids or short sequences of amino acids (e.g. about 2-5) in the sequence may be tolerated without vitiating the production and antigenicity of the fusion protein. Generally, such changes are not carried out in the heparin binding region of the protein, or at least such changes do not perturb the lysine residues which are methylated to yield the antigenic form of the protein.
- The HBHA protein whose primary amino acid sequence is set forth in SEQ ID NO: 3 was identified in and derived from M. tuberculosis and is a native Mtb sequence. However, those of skill in the art will recognize that other HBHA proteins may also be utilized in the practice of the invention. Generally, the HBHA is identified in or derived from (i.e. is native to) a mycobacterial species or strain, for example, various strains of M. bovis or M. tuberculosis, but may come from any source so long as it functions as described herein, i.e. advantageously large quantities of the protein may be produced as described herein (e.g. at least about 10 to about 300 or more (e.g. from about 15 to about 250, or from about 20 to about 200, or from about 15 to about 150, or from about 10 to about 100 μg HBHA per mg of total protein, with the range being generally from about 30 to about 100 g HBHA per mg of total protein). Regardless of the precise quantity, the antigenic quality of the protein is maintained, i.e. the antigenicity of the protein is comparable to that of the fusion protein represented by SEQ ID NO: 3, in terms of eliciting an immune response.
- Methods of growing bacterial cultures in order to produce protein are well known in the art, as are methods of obtaining, and isolating or purifying proteins produced in this manner. The invention encompasses methods of making the fusion protein described herein by transfecting (e.g. by electroporation) a suitable mycobacterial cell, growing the transfected cell under culture conditions which are suitable for the growth of the organism and production of the protein by the organism, and then obtaining and purifying the protein. Exemplary conditions and techniques are described in the Examples section below.
- In some embodiments, the nucleic acid that is introduced into the mycobacterial cell is contained within a vector such as a plasmid. However, other transfectable or transferable vectors may be used in the practice of the invention, e.g. various viral vectors, other episomal elements, etc. In addition, in some embodiments, the nucleic acids sequences of interest may be incorporated into the genome of the mycobacterium.
- The fusion protein that is produced and used in the practice of the present invention is, in some embodiments, substantially purified, e.g. a preparation of the protein is generally (e.g. at least 80, 90, 95, or even 99% or more) free of other proteins, as well as being free of other cellular components, e.g. nucleic acids, lipids, and other macromolecules. The rMyc of the invention may be employed as a biosource for rHBHA production and the rHBHA so-produced may be used for any purpose. In one embodiment, the purpose is to produce therapeutic immune response stimulating formulations of isolated, substantially purified fusion protein, which are discussed below.
- The bacterial cells that are used in the practice of the invention may be any that fulfill the criteria of being suitable for use in a vaccine preparation. e.g. they are attenuated (i.e. decreased in virulence or disease causing capacity; rendered innocuous or incapable of causing symptoms—or causing only minor symptoms—of disease, as is understood in the art); of not displaying antibiotic resistance; and being antigenic. In some embodiments, the cells are various species or variants of mycobacteria, (e.g. mutant or recombinant forms) of Mycobacterium tuberculosis, Mycotabcterium bovis, Mycobacterium smegmatis, or other mycobacteria, etc. In some embodiments, the bacterial cell is Mycotabcterium bovis BCG and/or various strains thereof, for example, mutant BCGs selected for a particular property, or recombinant BCGs that have been genetically manipulated. Exemplary recombinant BCGs are described, for example, in U.S. Pat. Nos. 7,625,572; 7,666,656; 7,829,104; and 8,043,857; all to Sun et al., the complete contents of each of which are hereby incorporated by reference. For example, the BCG may be genetically manipulated to contain and express an endosomolytic protein that is active at neutral pH (e.g. Perfringolysin O from Clostridium perfringens), and may also be auxotrophic and not antibiotic resistant, e.g. auxotrophic for the production of leucine, pantothenate, etc., or double auxotrophs such as leucine-pantothenate auxotrophs, etc. In some embodiments, the mycobacterial cell expresses a pfo gene. Exemplary pfo genes include but are not limited to those of bacteria such as Clostridium perfringens. However, those of skill in the art will recognize that other functionally similar proteins exist which could also be employed in the practice of the invention, either in their wild type form, or after being genetically modified to render them suitable. Examples of such endosomalytic proteins include but are not limited to Listeriolysin (Llo, produced by Listeria monocytogenes), Pneumolysin (produced by Streptococcus pneumoniae), Streptolysin O (produced by Streptococcus pyogenes), Cerolysin (produced by Bacilus cereus), α-hemolysin (produced by Staphylococcus aureus), etc. In one embodiment, the cell that is employed is a pantothenate auxotroph of a BCG Danish SSI strain expressing a Clostridium perfringens pfo gene, referred to herein as “AERAS-413”. However, those of skill in the art will recognize that other mycobactieral strains, e.g. other BCG strains such as BCG SSI without the pfo gene, Tokyo, Tice, etc., may also be employed as may those listed in, for example, U.S. Pat. No. 7,666,656, the complete contents of which is hereby incorporated by reference in entirety.
- The antigenically active form of the fusion protein of the invention is methylated. Generally, methylation is carried out by and within the rMyc cell, which, in some embodiments, has a native, intrinsic capacity to produce active methyltransferase enzymes. However, in some embodiments, the cell may be further modified to include nucleic acid sequences expressing additional methyltransferases, or further modified to produce higher levels of native methyltransferases.
- The present invention also provides compositions for use in eliciting an immune response against M. tuberculosis and/or vaccinating an individual against tuberculosis. In one embodiment, the compositions include, as an active agent, one or more rMyc species or strains, and a pharmacologically suitable carrier. In another embodiment, the compositions include, as an active agent, one or more substantially purified fusion proteins as described herein, and a pharmacologically suitable carrier. The preparation of such compositions for use as vaccines is well known to those of skill in the art. Typically, such compositions are prepared either as liquid solutions or suspensions, however solid forms such as tablets, pills, powders and the like are also contemplated. Solid forms suitable for solution in, or suspension in, liquids prior to administration may also be prepared. The preparation may also be emulsified. The active ingredients may be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredients. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol and the like, or combinations thereof. In addition, the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like. In addition, the composition may contain various adjuvants (compounds that can induce or increase the humoral and/or cellular immune response towards an antigen or immunogen). If it is desired to administer an oral form of the composition, various thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders and the like may be added. The composition of the present invention may contain any such additional ingredients so as to provide the composition in a form suitable for administration. The final amount of active agent in the formulations may vary. However, in general, the amount in the formulations will be from about 1-99%. Advantageously, an immunogenic composition of the invention comprises, per dose, from about 0.1 to about 50 μg of fusion protein, and generally from about 1 to 50 μg, e.g. about 15 μg of purified HBHA fusion protein. If the composition of the product comprises a live bacteria (e.g. an attenuated bacteria), the amount of bacteria per dose is generally in the range of from about 1×10 to about 1×10′, and is usually about 1×106.
- The compositions (preparations, formulations, etc.) of the invention may be administered by any of the many suitable means which are well known to those of skill in the art, including but not limited to by injection, intradermally, inhalation, orally, intravaginally, intranasally, by ingestion of a food or probiotic product containing the active agent, topically, as eye drops, via sprays, etc. In some embodiments, the mode of administration is by injection or intradermally. In addition, the compositions may be administered in conjunction with other treatment modalities such as substances that boost the immune system, various chemotherapeutic agents, other antigenic agents, various adjuvants, and the like.
- The invention also provides methods for eliciting an immune response in a subject in need thereof. The method involves, in one embodiment, administering a composition comprising the fusion protein of the invention, and in another embodiment, administering the rMyc of the invention. The immune response that is elicited may be one or both of innate and adaptive, and may involve both cell-mediated and humoral responses, for example, the production of antibodies, and/or a B cell and/or T cell response, etc. The response may be protective in that a recipient of the vaccine is protected against subsequent challenge with Mtb, thereby preventing the development of a TB infection, either active or latent. Further, if the compositions of the invention are administered after TB infection has occurred, the immune response may be such that a latent infection does not result, or, if a latent infection is already present, reactivation of the latent infection to active disease may be prevented, or the extent or severity of infection may be lessened.
- The invention also provides diagnostic tests which utilize the fusion protein of the invention. In particular, the tests are useful for identifying individuals who have a latent tuberculosis infection. The tests typically involve exposure of the immune cells or products of immune cells of a subject identified as possibly having latent TB (e.g. due to exposure to the disease, or for some other reason) to the protein and determining whether or not the immune cells or products thereof react to or recognize the fusion protein. In one embodiment, exposure is carried out by obtaining a biological sample from the subject (e.g. saliva, sputum, blood, plasma, etc.) and exposing the sample to the fusion protein in order to detect, e.g. the presence of anti-HBHA antibodies in the sample. In another embodiment, the fusion protein is injected intradermally (e.g. in the manner of the Mantoux or other similar tests) and the reaction of the skin to the protein is observed.
- In both embodiments, a positive reaction to the test indicates or confirms that the subject may or is likely to have a latent tuberculosis infection.
- In some embodiments the invention provides methods for producing cultures of the rMyc of the invention for use as seed lots. In particular, methods involving the batch production, purification and testing of the rMyc are encompassed. Such methods generally involve stepping up production of an initial clonal isolate, growing the isolate on a modest scale in media that is free of serum and animal origin protein, and then inoculating a culture of a desired larger volume (repeating this step as necessary until a sufficient volume is attained); and growing the rMyc culture under conditions that allow the rMyc to grow and undergo cell division. Generally, the rMyc is grown to a density (A600) of from about 4 to about 6, e.g. about 5. Aliquots of the culture are prepared e.g. for commercial purposes, either directly from the culture, or by concentrating the rMyc (e.g. by centrifugation) and resuspending the pellet in a suitable medium. The final amount of bacteria in a seed lot culture is generally on the order of from about 4×107 to about 6×107. Those of skill in the art are familiar with techniques for the long-term maintenance of such cultures, e.g. cryopreservation, lyophilization, etc. Prior to final preparation and storage of the rMyc cultures, the rMyc identity and purity may be tested/confirmed by methods known to those of skill in the art, e.g. by sampling the culture and analyzing it for the presence of the nucleic acid which encodes the fusion protein, or by analyzing it for the presence of the fusion protein itself.
- In other embodiments, the invention provides methods for producing a recombinant heparin-binding hemagglutinin (rHBHA) protein product. The methods comprise the steps of a) growing a culture of recombinant Mycobacteria comprising a nucleic acid fusion sequence encoding an Ag85B leader sequence attached to an amino terminus of a mycobacterial heparin-binding hemagglutinin (HBHA) protein, the fusion sequence being operably linked to a promoter, and obtaining the rHBHA protein from the culture. The Mycobacteria may have been genetically engineered to contain and express the nucleic acid fusion sequence. Growth of the culture may be carried out in any suitable manner, e.g. in shake culture, by fermentation, etc., and the culture may be, for example, a batch or continuous culture.
- The production methods typically also include a step of purifying the rHBHA protein. Purification of the protein may be carried out by any of the many suitable technologies that are known to those of skill in the art. Typically, the technology involves the use of one or more physico-chemical purification techniques. Exemplary techniques include but are not limited to: chromatography techniques such as ion exchange chromatography, affinity chromatography, size exclusion chromatography, hydrophobic interaction chromatography, etc.; as well as various cell disruption techniques such as high pressure cell disruption, the use of bead beaters, homogenization, sonication, centrifugation, etc. Combinations of these and other techniques may also be employed.
- The methods may also include a step of verifying the identity of the rHBHA protein. Those of skill in the art are familiar with suitable techniques for verifying the identity and/or purity of proteins and polypeptides. Exemplary techniques include but are not limited to: electrophoresis, chromatography, mass spectrometry, amino acid sequencing, etc.
- The methods may also include a step of combining purified rHBHA protein with a physiologically acceptable carrier. Suitable physiologically acceptable or compatible carriers are described elsewhere herein. In some embodiments, the formulated HBHA protein product further comprises one or more other active agents. For example, one or more antigens that are not HBHA (i.e. a non-HBHA antigen) may be included. Exemplary additional antigens include but are not limited to, for example, those which elicit an immune response against diseases such as diphtheria; pertusis; tetanus; polio, influenza, hepatitis, rotavirus, pneumonia, measles, mumps, rubella, varicella, meningitis, papillomavirus, etc. The rHBHA protein product may also include one or more adjuvants and/or one or more immunogenicity enhancers, examples of which include but are not limited to: mineral salts e.g., aluminum hydroxide (“alum”), aluminium phosphate, calcium phosphate; oil emulsions e.g., MF59, a detergent-stabilised oil-in-water emulsion; particulate adjuvants e.g., virosomes, ISCOMS (structured complex of saponins and lipids); microbial derivatives e.g., MPL(TM) (monophosphoryl lipid A), CpG motifs, modified toxins, etc; various plant derivatives e.g., saponins (QS-21); as well as endogenous immunostimulatory adjuvants e.g., cytokines, heat shock proteins (HSPs) and fragments thereof, etc.
- The forgoing examples serve to further illustrate particular embodiments of the invention but should not be interpreted as limiting the invention in any way.
- The purpose of these studies was to develop a recombinant M. bovis BCG strain over-expressing HBHA A recombinant BCG strain previously constructed at Aeras (AERAS-413) was used because it is a panCD auxotroph and the presence of panCD on the plasmid with the HBHA gene was used for complementation and colony selection in the absence of antibiotic resistance.
- Initial cloning steps were carried out in Escherichia coli stbl3 cells grown in LB supplemented with kanamycin (40 ug/ml). For the over expression of HBHA, a pantothenate auxotroph of a BCG Danish SSI strain expressing the pfo gene from Clostridium perfringens (AERAS-413) that facilitates antigen presentation through endosome escape mechanisms was utilized (1) The BCG strain was grown in Middle brook 7H9-broth and supplemented with glycerol, OADC and D-pantothenic acid (25 ug/ml). The parent and the recombinant BCG were plated on 7H10-OADC plates with and without pantothenate supplement respectively.
- The Mtb sequence for HBHA gene was taken from the Tuberculist website and was synthesized (DNA 2.0) along with the Ag85B promoter and leader peptide in front of the start HBHA codon (
FIGS. 1A, 1B, and 2 ). - The synthesized fragment was cloned between sites PacI and SpeI in pKAMCB2 vector which is an E. coli-mycobacterial shuttle vector with a kanamycin resistance marker (aph) and a complementing panCD gene operated via the hsp60 promoter (
FIGS. 3A and 3B ). This plasmid was used so that it could complement the panCD auxotrophy in AERAS-413 and also maintain the stability of the plasmid in AERAS-413. Once cloned, the antibiotic marker was digested out with HpaI enzyme and the construct was self-ligated to make it “antibiotic resistant marker free” (FIG. 4 ). The self-ligated construct was electroporated into AERAS-413 and the recovered colonies were plated onto 7H10-plates without pantothenate supplement and without antibiotics. The colonies were screened for the presence of the antigen, the plasmid backbone and the absence of the kanamycin antibiotic resistance marker. - Native HBHA has 100% sequence identity in both BCG and Mtb. The recombinant HBHA is expressed using Ag85B promoter and Ag85B leader peptide fused to the N-terminus of the protein (
FIGS. 5A, 5B, and 5C ). - Genotypic Analysis of the Colonies from AERAS-413
- The colonies from AERAS-413 plates transformed with the pKAMCB2 derivative containing the HBHA gene were screened for the presence of the full length Ag85B-HBHA construct in the plasmid. The primers used for this PCR were Ag-HBHA.for: GGTCTTCGTCGGCTTGCTTC (SEQ ID NO: 6) and Ag-HBHA.rev: GCTCTGCCAGTGTTACAACC (SEQ ID NO: 7) and the product size of 2.6 kb was expected which is seen in the colony No. 5 (
FIGS. 6A, 6B, and 6C ). The same colonies were tested for the presence of the plasmid backbone spanning from the oriM to panCD complementing gene and for the absence of the antibiotic resistance marker. Primers used for the plasmid backbone were oriM7932.for GTCTACGAGGCCACACTCAG (SEQ ID NO: 8) and pan9969.rev TATCGCGCAGCTCCAGGTAG (SEQ ID NO: 9). Primers used for checking the kanamycin antibiotic marker m the plasmid were kan_intrnl.for GCTCGAGGCCGCGATTAAATTC (SEQ ID NO: 10) and kan_intrnl.rev GGATGGCAAGATCCTGGTATCG (SEQ ID NO: 11). Colony No. 5 shows the presence of the plasmid backbone and also the absence of the kanamycin gene from the backbone making it antibiotic marker less. The recombinant AERAS-413 strain over-expressing HBHA was named AERAS-445 and was used for further phenotypic analysis and scale-up manufacturing. (FIGS. 6A, 6B, and 6C ) - AERAS-445 grown under conditions described above was observed to have a similar growth pattern to that of the parent strain AERAS-413 as well as AERAS-401. The seed culture was diluted to the OD600 of 0.2 and the absorbance was measured over 9 days to observe the growth pattern. The growth pattern for AERAS-445 was very similar to that of the parent strain indicating that the over-expressed HBHA protein did not have any detrimental effect on the growth kinetics (
FIG. 7 ) - Phenotypic Analysis of the Colonies from AERAS-413
- Cultures were grown in protein-free 7H9 media to an OD600=1.0. Cultures were spun at 3,000 rpm for ten minutes to separate the supernatant and pellets. To process the pellets for cell lysates, the pellets were resuspended in a protease inhibitor cocktail buffer and then treated by bead beating to disrupt the cells. The lysates were centrifuged at 3,000×g at 4 degrees to remove debris. Cell lysate protein concentrations were measured by BCA (bicinchoninic acid) protein assay. Normalization of samples was performed by loading equal amounts of protein, which was thirty micrograms. Samples were prepared by heating at 70 degrees for fifteen minutes with reducing agent and loading dye. Samples were then loaded onto gradient (4-12% Bis-Tris) polyacrylamide gels and run with MOPS buffer. The transfer was done using the iBlot® Dry blotting system for six minutes. Western blot analysis was done using the Snap i.d. system (Millipore). The primary antibody used was either the anti-HBHA monoclonal 4057D2 (2) (1:2000), or 1G10 (1:1000) anti-HBHA antibody followed by use of goat anti-mouse HRP secondary antibody (KPL). Detection was done by HRP chemiluminescence (Immun-Star, Biorad).
- In
FIG. 8 ,Arrow 1 indicates the recombinant HBHA in AERAS-445 and its absence in the control parent strain AERAS-413 andarrow 2 indicates the native HBHA present in both control AERAS-413 and recombinant AERAS-445. The 4057D2 monoclonal antibody, which recognizes the methylated portion of the HBHA protein, indicated that the recombinant HBHA produced in AERAS-445 is methylated. The Western blot procedure was repeated with the monoclonal antibody 1G10 developed at the Institut Pasteur de Lille, France. AERAS-401 and AERAS-413 was used as controls in this blot.Arrow 1 indicates the presence of recombinant HBHA in AERAS-445 and its absence in the control parent strains AERAS-401 and AERAS-413 andarrow 2 indicates the native HBHA is present in both the controls and recombinant strains. Unlike the 4057D2 antibody, 1G10 recognizes a specific epitope within the non-methylated region of the HBHA protein (FIG. 9 ). - cGMP Manufacturing of HBHA from the AERAS-445 Strain
- Through a gradual reduction in animal-protein concentration, the recombinant BCG (rBCG) was adapted to grow in media free from serum and animal origin protein. The final product is a concentrated accession cell bank of 4.5±0.4 mL per vial stored at vapor phase of liquid nitrogen which can be used for the inoculation, e.g. for cGMP Master Cell Bank Production.
- In order to adapt the rBCG to growing in a serum and animal origin protein free medium, the use of Oleic Albumin Dextrose Catalase (OADC) supplement in the culture medium during ACB establishment was prohibited. Table 1 summarizes the process of converting to serum animal origin protein free medium. The medium used for ACB construction was Modified Middle brook 7H9 Medium (MM7H9) without OADC or any other serum or animal derived supplement. The first stage culture was grown in a 500 mL venti-cap flask with no baffles. All cultures after the first stage were grown in baffled shaker flasks.
-
TABLE 1 AERAS-445 Growth Guidelines for Accession Cell Bank Flask OADC Vol. Vol. Inoc. Total Centrifuge Pass/ Size conc. MM7H9 OADC Vol. Vol. Target At Spec Stage (mL) (%) (mL) (mL) (mL) (mL) A600 (yes/no)? 1 500 0 95 0 5.0 100 4 ± 1.5 No 2 2000 0 900 0 100 1000 4 ± 1.5 No 3 2000 0 850 0 150 125 4 ± 1.5 Yes - After the culture reached its final passage, it was harvested/recovered. The culture was centrifuged at 1200×g for 30 min at 6±4° C. and re-suspended in 10% GST solution stored at room temperature at ¼ the original volume (Table 1). The culture was then dispensed in 4.0±0.5 mL aliquots into 5 mL sterile cryovials. The vials were stored in the vapor phase on liquid nitrogen.
- Two vials of post-freeze AERAS-445 were tested for sterility. The results were negative for any growth contaminants. Vials containing 4× concentrated AERAS-445 rBCG were frozen at vapor phase liquid nitrogen. As shown in
FIG. 10 , a Western blot with the anti-HBHA monoclonal antibody 1G10 shows the production of the target antigen (HBHA) from cell lysates of AERAS-445 frozen cultures. -
- 1. Prepare growth media and freezing media.
- a. R&D Style Middle brook 7H9
-
4.7 g/L Middle brook 7H9 Powder 0.24% (v/v) Glycerol 0.05% (w/v) Tyloxapol 10% (v/v) OADC Supplement -
- b. Modified Middle brook 7H9
-
4.7 g/L Middle brook 7H9 Powder 2.0 g/ L Sodium Glutamate 2% (v/v) Glycerol 3 mg/L Zinc Sulfate Heptahydrate 0.2 g/L Magnesium Sulfate Heptahydrate 0.05% (v/v) Tyloxapol 1.0% (w/v) Dextrose 0% OADC Supplement -
- c. 10% GST Solution
- 10% (v/v) Glycerol
- 0.85% (w/v) Sodium Chloride
- 0.05% (v/v) Tyloxapol
- c. 10% GST Solution
- 2. 5 mL of live AERAS-445 culture from Kamal Velmurugan (Vaccine Discovery) was inoculated into a 500 mL shake flask containing prewarmed 95 mL culture containing Modified Middle brook 7H9 medium without OADC.
- 3. For the rest of the process Modified Middle brook 7H9 medium was used.
- 4. The culture was incubated in a shaker/incubator (Aeras #1230) at 37° C. and 125 rpm.
- 5. The absorbance was measured at 600 nm when culture has a visual change in turbidity.
- 6. Once culture reached A600=4.0±1.5 AU, it was inoculated into the second stage (900 mL working volume in 2 L shake flask with venti-cap) with the
entire stage 1 culture (˜90 mL). - 7. The culture was incubated in a shaker/incubator (Aeras #1230) at 37° C. and 125 rpm.
- 8. The absorbance was measured at 600 nm when culture has a visual change in turbidity.
- 9. Once culture reached A600=3.0±1.5 AU, it was inoculated into the Stage 3 (850 mL MM7H9 medium without OADC) with 150 mL of the
Stage 2 culture. Total 3×2 L shake flasks (working volume 1 L/flask) were inoculated. - 10. The culture was incubated in a shaker/incubator at 37° C. and 125 rpm.
- 11. The absorbance was measured at 600 nm when culture has a visual change in turbidity.
- 12. Once the culture (Stage 3) reached A600=4±1.5 AU, the flask with median A600 readout was selected and harvesting process was initiated.
- 13. The selected
Stage 3 culture was centrifuged in a pre-autoclaved 1 L centrifuge tube for 30 minutes at 1200×g and 4° C. - 14. The supernatant was discarded and the pellet was re-suspended in ¼ volume (˜250 mL) of 10% GST.
- 15. While maintaining mixing, 5 mL cryo-vials were filled with 4.0±0.5 mL of the re-suspended cells.
- The filled vials were immediately frozen in vapor phase of liquid nitrogen.
- The amount of HBHA produced in AERAS-445 was estimated by a sandwich ELISA method developed at the Institut Pasteur de Lille. The primary monoclonal antibody was 1G10 and the secondary monoclonal antibody was biotinylated 5F2, developed at the Institut Pasteur de Lille (EZ-link Sulfo-NHS-LC-Biotin, Pierce). In short, 100 ul per well of mAb 1G10 at 5 ug/ml diluted in coating buffer was seeded on to high affinity binding ELISA plate and incubated over night at 4° C. The plate was washed twice and blocked with PBS-Tween20 (+1% BSA) for 1 hour. Recombinant and native HBHA were diluted with 1×PBS (8 dilutions) and 100 ul were added onto each well and incubated for 2 hours. After three washes with 1×PBS-Tween20, 100 ul of the mAb 5F2 at a concentration of 0.2 ug/ml was added and incubated for 1 hour. The wells were washed thrice and 100 ul Streptavidin-HRP (BD biosciences) conjugate was added at concentration of 1/1000 in PBS and incubated for 30 mins at room temperature. The protein was detected with 100 ul of TMB substrate (ELISA peroxide substrate) and developed at room temperature for 5 mins to 15 mins. The reaction was stopped with 50 ul of 3M H3PO4 and the optical density was read at 450 nm. From this result AERAS-445 expressed almost 8-fold more HBHA compared to the parent strain (
FIGS. 11A and 11B ). - The yield of HBHA from the M. bovis BCG Pasteur 1173P2 was also compared with
AERAS 445. The BCG strains were grown in 200 ml agitated Sauton medium in 1-liter flasks for 10 days until the optical density reading at 600 nm reached approximately 1.5. The BCG cells were then harvested by centrifugation at 8,500 rpm (Beckmann J2MC centrifuge, rotor JA 0). The BCG pellet was then suspended in 20 ml PBS+0.05% Tween 80 (Tw 80: Sigma Ultra, ref P8074) and centrifuged at 6,500 rpm (Beckman Coulter Allegra 64R, rotor F0650) for 20 min at 4° C. The pellet was the weighted before suspension in 20 ml PBS+0.05% Tween 80, heat inactivated and sonicated as described below. The supernatant of the sonicate was then analyzed for its protein content and for the concentration of HBHA by using the Sandwich ELISA with the monoclonal antibodies 1G10 and 5F2, as described above. An average of 3 to 4 independent measurements indicated that BCG Pasteur 1173P2 produces approximately 10 μg HBHA/mg of total protein, whereasAERAS 445 produces an average of approximately 19 μg HBHA/mg of total protein. ThisAERAS 445 produces roughly twice as much HBHA as BCG Pasteur 1173P2. - Purification of rHBHA from
AERAS 445 - Pellets of
AERAS 445 were resuspended in 20 ml PBS+0.05% Tween80 (Tw 80, Sigma Ultra, ref. P8074) and centrifuged at 6,500 rpm (Beckman Coulter Allegra 64R, rotor F0650) for 20 min. at 4° C. The pellets were weighted and resuspended in 20 ml PBS+0.05% Tween 80, heated for 30 min. at 80° C. and centrifuged for 20 min. at 12,000 rpm (Beckman Coulter Allegra 64R, rotor F0650) at 4° C. - 1.5 g of heat-inactivated
AERAS 445 was suspended in 15 ml PBS+0.05% Tween80 and sonicated on ice with an Analog sonifier unit model S-450A (Branson, US) for 20 min. (output 7, duty cycle 90) with a flat disrupter horn (13 mm, VWR ref. 142-3751). The sonicate was centrifuged at 13,500×g for 20 min, and the supernatant was applied onto a heparin-Sepharose CL-B column (1×5 cm) equilibrated with DPBS. The column was then washed with 100 ml DPBS, and the bound material was eluted by a 0-500 mM NaCl gradient in 100 ml DPBS. The eluted 1-ml fractions were identified by SDS-PAGE using a 12% gel followed by Coomassie Brilliant Blue R-250 staining. - The HBHA-containing fractions were pooled and applied onto a reverse-phase HPLC Nucleosil C18 column (TSK gel super ODS; Interchim) equilibrated in 0, 05% trifluoroacetic acid. Bound material was eluted with a linear 0-80% acetonitrile gradient. HBHA-containing fractions were pooled, and the solvent was eliminated by evaporation. The pH of the final fraction of 1 ml was adjusted to pH8 by using 1 M Tris-HCl (pH9). The final product was stored at −80° C. HBHA-containing fractions were analyzed by SDS-PAGE, mass spectrometry and sandwich ELISA using the 1G10 and the 5F2 monoclonal antibodies, as described above.
-
FIG. 12 shows a mass-spectrometry analysis of purified rHBHA fromAERAS 445. For the mass-spectrometry analysis, the protein (0.1 to 10 pmol) was prepared by the dry droplet method. The protein solution (0.5 μl) was mixed with freshly dissolved a-cyano4-hydroxycinnaminic acid at 10 mg/ml in 50% CH3CN and 0.1% trifluoroacetic acid. After spotting and drying, mass spectrometry analysis was performed by using a matrix-assisted laser desorption ionization/time-of-flight (Voyager-DE-STR, Applied Biosystems). The following setting parameters were used: positive and linear modes, acceleration voltage of 25 kV, grid voltage of 92%, 750 ns of delayed extraction time, and low mass gate of 1,000 Da. The spectra were calibrated externally by using the [M+H+] monoisotopic ions of different peptides for average masses of E. coli thioredoxin and horse apomyoglobin (Applied Riosystems). - Mass Spectrometry Analysis of rHBHA Methylation Pattern
- Purified rHBHA was digested overnight with 5% endoproteinase Glu-C(Roche), and the resulting peptides were separated by reverse-phase HPLC using a Beckman Ultra sphere ODS column (2×200 mm) and a linear 0-60% acetonitrile elution gradient prepared in 0.1% trifluoroacetic acid and directly analyzed by mass spectrometry.
- For mass spectrometry, the peptide solution was mixed with freshly dissolved a-cyano4-hydroxycinnaminic acid at 10 mg/ml in 50% CH3CN and 0.1% trifluoroacetic acid. After spotting and drying, mass spectrometry analysis was performed by using a matrix-assisted laser desorption ionization/time-of-flight Voyager-DE-STR (Applied Biosystems). For peptides between 3,000 Da to 10,000 Da, the following setting parameters were used: positive and reflector modes, acceleration voltage of 25 kV, grid voltage of 65%, 250 ns of delayed extraction, and low mass gate of 1,000 Da. The spectra were calibrated externally by using the [M+H+] monoisotopic ions of different peptides for average masses of E. coli thioredoxin and horse apomyoglobin (Applied Biosystems).
- The results of the mass spectrometry analysis of rHBHA purified from
AERAS 445 are depicted inFIG. 13 and indicate that the C-terminal end of the protein shows heterogeneity, consistent with the complex methylation profile expected for HBHA. - Reaction of Different Forms of HBHA with Monoclonal Antibodies 4057D2 and 3921E4
- The concentration of purified rHBHA from
AERAS 445 was measured and adjusted in order to coat overnight at 4° C. 1 μg per well of ELISA plates. The plates were then washed with phosphate buffered saline (PBS)/Tween (PBST), followed by blocking for 2 hrs at room temperature with PBST containing 3% BSA. After washing again three times with PBST, the plates were incubated for 1 h30 at room temperature with serial four-fold dilutions of monoclonal antibodies 3921E4 or 4057D2 in PBST+BSA. The latter two preferentially recognize the methylated forms of HBHA (3). The plates were then washed 10 times with PBST and incubated for 1 h at room temperature with anti-mouse antibodies linked to peroxidase. After 10 additional washings with BPST, 100 μl of peroxidase substrate TMB was added to each well, and the colour reaction was stopped by the addition of 50 μl H3PO4. Finally the absorbency at 450 nm was read in each well using a standard ELISA plate reader.FIGS. 14A and 14B show that rHBHA fromAERAS 445 is recognized by both the 4057D2 and the 3921E4 monoclonal antibodies, confirming that it is properly methylated. - Antigenicity of rHBHA from
AERAS 445 in Latently Infected Humans - Purified rHBHA from
AERAS 445 was incubated at 2 g/ml with 106 peripheral blood mononuclear cells (PBMC) isolated from three latently infected human subjects, three patients with active tuberculosis and from three negative control subjects. After 96-hours, the IFN-γ concentrations released in the supernatants were measured by ELISA, and the IFN-γ secretion from unstimulated PBMC was subtracted from the antigen-induced IFN-γ secretion. The sensitivity of the IFN-γ (ELISA was 10 μg/ml. The cut-off value for optimal discrimination between non-infected controls and LTBI subjects was previously determined to be 100 pg/ml for HBHA (4). As shown in Table 2, rHBHA purified fromAERAS 445 is well recognized by the PBMCs from latently infected individuals, poorly recognized by the PBMCs from tuberculosis patients and not recognized by the PBMCs from healthy controls. -
TABLE 2 Human T cell antigenicity of HBHA. The PBMC from 9 human subjects (3 latently infected subjects Nos. 1, 8 and 9; three active tuberculosis patients Nos. 2, 3 and 4 and 3 negative controls Nos. 5, 6 and 7) were incubated with 2 μg/ml of HBHA from M. bovis BCG Pasteur 1173P3 (IPL) or AERAS 445 (Aeras). and the resulting IFN-g concentrations were measured in the culture supernatants and are expressed as ng/ml HBHAIPL HBHAAeras* Patient Number (BCG Pasteur) (AERAS-445) 1 5.21 13.53 2 0.09 0.02 3 0.02 0.11 4 0.24 0.27 5 0.07 0.12 6 <0.01 <0.01 7 <0.01 <0.01 8 1.43 .73 9 1.62 1.28 -
- 1. Sun R, Skeiky Y A, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J. Scanga C, Grover A, Derrick S C, Morris S, Hone D M, Horwitz M A, Kaufmann S H, Sadoff J C. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine. 2009 Jul. 16; 27(33):4412-23.
- 2. Rouse D A, Morris S L, Karpas A B, Mackall J C, Probst P G, Chaparas S D. Immunological characterization of recombinant antigens isolated from a Mycobacterium avium lambda gt11 expression library by using monoclonal antibody probes. Infect Immun. 1991 August; 59(8):2595-600
- 3. Pethe et al. 2002. Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc. Natl. Acad. Sci. USA 99, 10759-10764
- 4. Hougardy J-M, Schepers K, Place S, et al. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS ONE 2007; 2: e926.
- 5. Temnmerman S, Pethe K, Parra M, Alonso S, Rouanet C, Pickett T, Drowart A, Debrie A S, Delogu G, Menozzi F D, Sergheraert C, Brennan M J, Mascart F, Locht C. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med. 2004 September; 10(9):935-41
- 6. Zanetti S, Bua A, Delogu G, Pusceddu C, Mura M, Saba F, Pirina P, Garzelli C, Vertuccio C, Sechi L A, Fadda G. Patients with pulmonary tuberculosis develop a strong humoral response against methylated heparin-binding hemagglutinin. Clin Diagn Lab Immunol. 2005 September; 12(9):1135-8
- While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/827,151 US20180305416A1 (en) | 2012-04-16 | 2017-11-30 | Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2012/033757 WO2013158061A1 (en) | 2012-04-16 | 2012-04-16 | Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof |
US201514394689A | 2015-06-25 | 2015-06-25 | |
US15/827,151 US20180305416A1 (en) | 2012-04-16 | 2017-11-30 | Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/394,689 Continuation US9926346B2 (en) | 2012-04-16 | 2012-04-16 | Recombinant mycobacterium encoding a heparin-binding hemagglutinin (HBHA) fusion protein and uses thereof |
PCT/US2012/033757 Continuation WO2013158061A1 (en) | 2012-04-16 | 2012-04-16 | Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180305416A1 true US20180305416A1 (en) | 2018-10-25 |
Family
ID=49383839
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/394,689 Expired - Fee Related US9926346B2 (en) | 2012-04-16 | 2012-04-16 | Recombinant mycobacterium encoding a heparin-binding hemagglutinin (HBHA) fusion protein and uses thereof |
US15/827,151 Abandoned US20180305416A1 (en) | 2012-04-16 | 2017-11-30 | Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/394,689 Expired - Fee Related US9926346B2 (en) | 2012-04-16 | 2012-04-16 | Recombinant mycobacterium encoding a heparin-binding hemagglutinin (HBHA) fusion protein and uses thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US9926346B2 (en) |
EP (1) | EP2838990A4 (en) |
JP (1) | JP2015515276A (en) |
CN (1) | CN104508120A (en) |
IN (1) | IN2014DN08675A (en) |
WO (1) | WO2013158061A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019144139A1 (en) * | 2018-01-22 | 2019-07-25 | Oregon State University | Immunogenic compositions comprising mycobacterium bovis surface proteins and uses thereof |
AU2019257190A1 (en) * | 2018-04-17 | 2020-11-19 | The Johns Hopkins University | Recombinant therapeutic interventions for cancer |
CN112746051A (en) * | 2020-12-24 | 2021-05-04 | 中国人民解放军空军特色医学中心 | Recombinant mycobacterium smegmatis strain for expressing methylated HBHA protein, preparation method and application thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6641814B1 (en) * | 1997-04-02 | 2003-11-04 | Statens Serum Institut | Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis |
US6949345B1 (en) | 1996-05-17 | 2005-09-27 | Institut National De La Sante Et De La Recherche Medicale | Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin |
AU740545B2 (en) * | 1997-04-02 | 2001-11-08 | Statens Serum Institut | Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis |
US7745141B2 (en) | 2001-06-21 | 2010-06-29 | New York University | Mycobacterial proteins as early antigens for serodiagnosis and vaccines |
FR2832410B1 (en) | 2001-11-19 | 2004-04-02 | Pasteur Institut | RECOMBINANT MYCOBACTERIAL ANTIGEN OF HEMAGGLUTININ TYPE OF METHYLATED HEPARIN BINDING, METHODS OF PREPARATION AND IMMUNOGENIC COMPOSITIONS COMPRISING SUCH ANTIGEN |
JP4838259B2 (en) * | 2004-11-16 | 2011-12-14 | クルセル ホランド ベー ヴェー | Multivalent vaccine containing recombinant viral vectors |
BRPI0518091A2 (en) | 2004-12-01 | 2008-11-25 | Aeras Global Tb Vaccine Foundation | mycobacterium, Method for allowing a mycobacterium to escape from endosomes and preparation for a vaccine |
US7829104B2 (en) | 2004-12-01 | 2010-11-09 | Aeras Global Tb Vaccine Foundation | Electroporation of Mycobacterium and overexpression of antigens in mycobacteria |
EA012182B1 (en) | 2004-12-01 | 2009-08-28 | ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН | Electroporation of mycobacterium and overexpression of antigens in mycobacteria |
GB0500102D0 (en) | 2005-01-05 | 2005-02-09 | Isis Innovation | Method for generating a memory t cell response |
CN1966689A (en) * | 2005-11-15 | 2007-05-23 | 华中科技大学 | BCG vaccine expression vector and its construction |
US20120201846A1 (en) * | 2009-07-29 | 2012-08-09 | Bernd Helmut Adam Rehm | Polymer particles and uses thereof |
CN101816783B (en) * | 2010-04-15 | 2013-02-06 | 中国人民解放军第四军医大学 | Recombinant Mycobacterium smegmatis vaccine expressing HBHA-IL-12 fusion protein |
GB201008512D0 (en) | 2010-05-21 | 2010-07-07 | Health Prot Agency | Mycobacterial antigen composition |
EP2437061A1 (en) | 2010-09-30 | 2012-04-04 | Ikonomopoulos, John | Mycobacterial protein detection |
-
2012
- 2012-04-16 WO PCT/US2012/033757 patent/WO2013158061A1/en active Application Filing
- 2012-04-16 EP EP12874533.8A patent/EP2838990A4/en not_active Withdrawn
- 2012-04-16 IN IN8675DEN2014 patent/IN2014DN08675A/en unknown
- 2012-04-16 US US14/394,689 patent/US9926346B2/en not_active Expired - Fee Related
- 2012-04-16 CN CN201280073116.7A patent/CN104508120A/en active Pending
- 2012-04-16 JP JP2015506943A patent/JP2015515276A/en active Pending
-
2017
- 2017-11-30 US US15/827,151 patent/US20180305416A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150291669A1 (en) | 2015-10-15 |
EP2838990A1 (en) | 2015-02-25 |
JP2015515276A (en) | 2015-05-28 |
WO2013158061A1 (en) | 2013-10-24 |
CN104508120A (en) | 2015-04-08 |
EP2838990A4 (en) | 2016-08-10 |
US9926346B2 (en) | 2018-03-27 |
IN2014DN08675A (en) | 2015-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Olaya-Abril et al. | Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae | |
CA2759583C (en) | A tuberculosis tb vaccine to prevent reactivation | |
KR102515835B1 (en) | Uspa2 protein constructs and uses thereof | |
EP2912056B1 (en) | M. tuberculosis vaccines | |
CN102164952B (en) | New compositions and method | |
US20210268094A1 (en) | Engineering gut commensal bacteria to express heterologous proteins in their outer membrane vesicles (omvs) for delivery to the gi-tract | |
CN105120892B (en) | Immunogenic compositions comprising elements of clostridium difficile CDTB and/or CDTA protein | |
US10010595B2 (en) | Live recombinant booster vaccine against tuberculosis | |
US20200148729A1 (en) | Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections | |
US20180305416A1 (en) | Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof | |
Bai et al. | Expression and purification of Mycobacterium tuberculosis ESAT-6 and MPT64 fusion protein and its immunoprophylactic potential in mouse model | |
Cho et al. | Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus | |
CN106536544B (en) | Clostridium difficile immunogenic compositions | |
Mon et al. | Evaluation of cocktails with recombinant proteins of Mycobacterium bovis for a specific diagnosis of bovine tuberculosis | |
CN107349423B (en) | Meningococcal antigen combination and application thereof | |
CN111948387B (en) | Application of mycobacterium tuberculosis antigen protein Rv1485 in preparation of tuberculosis vaccine | |
JP2018134074A (en) | Recombinant mycobacterium encoding heparin binding hemagglutinin (hbha) fusion protein and uses thereof | |
US20230045642A1 (en) | S. aureus antigens and compositions thereof | |
WO2016091912A1 (en) | Neisseria meningitidis trypsin-like serine protease polypeptides and compositions thereof | |
WO2022013160A1 (en) | Streptococcal vaccines | |
Sergienko et al. | Preparation of mycobacterial antigens fused with a cellulose-binding domain with the aim of developing a subunit antituberculous vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AERAS GLOBAL TB VACCINE FOUNDATION, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FULKERSON, JOHN;VELMURUGAN, KAMALAKANNAN;BRENNAN, MICHAEL;SIGNING DATES FROM 20170511 TO 20170612;REEL/FRAME:046461/0076 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LOCHT, CAMILLE;REEL/FRAME:046461/0226 Effective date: 20170523 Owner name: AERAS, MARYLAND Free format text: CHANGE OF NAME;ASSIGNOR:AERAS GLOBAL TB VACCINE FOUNDATION;REEL/FRAME:046629/0062 Effective date: 20110310 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |